nctId,ec_single,ner,relation
NCT02836548,Inclusion: Histological proof of advanced melanoma with BRAF V600 mutation;,"```json
[
    {
        ""entity"": ""Histological proof"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""advanced melanoma"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""BRAF V600 mutation"",
        ""category"": ""Observation""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Histological proof""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""advanced melanoma""
    },
    {
        ""id"": 3,
        ""type"": ""Observation"",
        ""name"": ""BRAF V600 mutation""
    }
]
```"
NCT02836548,"Inclusion: Progression of disease, according to RECIST 1.1, while on treatment with BRAFi, such as vemurafenib or dabrafenib; or a combination of BRAF - and MEK inhibitors, such as trametinib and dabrafenib;","```json
[
    {
        ""entity"": ""Progression of disease"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""RECIST 1.1"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""treatment with BRAFi"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""vemurafenib"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""dabrafenib"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""combination of BRAF - and MEK inhibitors"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""trametinib"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""dabrafenib"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Progression of disease""
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""RECIST 1.1""
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""treatment with BRAFi""
    },
    {
        ""id"": 4,
        ""type"": ""Drug/Substance"",
        ""name"": ""vemurafenib""
    },
    {
        ""id"": 5,
        ""type"": ""Drug/Substance"",
        ""name"": ""dabrafenib""
    },
    {
        ""id"": 6,
        ""type"": ""Drug/Substance"",
        ""name"": ""combination of BRAF - and MEK inhibitors""
    },
    {
        ""id"": 7,
        ""type"": ""Drug/Substance"",
        ""name"": ""trametinib""
    },
    {
        ""id"": 8,
        ""type"": ""Drug/Substance"",
        ""name"": ""dabrafenib""
    }
]
```"
NCT02836548,Inclusion: Previous documented response (partial or complete) for at least 4 weeks to treatment with BRAFi and/or BRAFi+MEKi;,"```json
[
    {
        ""entity"": ""Previous documented response (partial or complete)"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""at least 4 weeks"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""treatment with BRAFi and/or BRAFi+MEKi"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Previous documented response (partial or complete)""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""treatment with BRAFi and/or BRAFi+MEKi"",
        ""temporal"": {
            ""start"": {
                ""number"": 4,
                ""unit"": ""weeks""
            }
        }
    }
]
```"
NCT02836548,Inclusion: Start with vorinostat treatment within a maximum period of 1 week after discontinuation of BRAFi and/or BRAFi+MEKi.,"```json
[
    {
        ""entity"": ""vorinostat treatment"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""within a maximum period of 1 week"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""discontinuation of BRAFi and/or BRAFi+MEKi"",
        ""category"": ""Qualifier/Modifier""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Drug/Substance"",
        ""name"": ""vorinostat treatment"",
        ""temporal"": {
            ""end"": {
                ""number"": 1,
                ""unit"": ""week""
            }
        }
    }
]
```"
NCT02836548,Inclusion: Age ≥ 18 years;,"```json
[
    {
        ""entity"": ""Age"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""≥ 18 years"",
        ""category"": ""Measurement""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Age"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 18,
                ""upper_bound"": null,
                ""unit"": ""years""
            }
        }
    }
]
```"
NCT02836548,Inclusion: Able and willing to give written informed consent;,"```json
[]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Type 2 diabetes mellitus""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""Metformin""
    },
    {
        ""id"": 3,
        ""type"": ""Measurement"",
        ""name"": ""Serum creatinine""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""Chemotherapy""
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""Smoking""
    },
    {
        ""id"": 6,
        ""type"": ""Observation"",
        ""name"": ""30 to 75 years old"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 30,
                ""upper_bound"": 75,
                ""unit"": ""years""
            }
        }
    }
]
```"
NCT02836548,"Inclusion: WHO performance status of 0, 1 or 2;","```json
[
    {
        ""entity"": ""WHO performance status"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""0, 1 or 2"",
        ""category"": ""Measurement""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""WHO performance status"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 0,
                ""upper_bound"": 2,
                ""unit"": """"
            }
        }
    }
]
```"
NCT02836548,Inclusion: Able and willing to undergo blood sampling for PK and PD analysis;,"```json
[
    {
        ""entity"": ""Able and willing"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""blood sampling"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""PK and PD analysis"",
        ""category"": ""Procedure/Device""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Able and willing""
    },
    {
        ""id"": 2,
        ""type"": ""Procedure/Device"",
        ""name"": ""blood sampling""
    },
    {
        ""id"": 3,
        ""type"": ""Procedure/Device"",
        ""name"": ""PK and PD analysis""
    }
]
```"
NCT02836548,Inclusion: Life expectancy ≥ 3 months allowing adequate follow up of toxicity evaluation and antitumor activity;,"```json
[
    {
        ""entity"": ""Life expectancy"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""≥ 3 months"",
        ""category"": ""Measurement""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Life expectancy"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 3,
                ""unit"": ""months""
            }
        }
    }
]
```"
NCT02836548,Inclusion: Evaluable disease according to RECIST 1.1;,"```json
[
    {
        ""entity"": ""Evaluable disease"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""RECIST 1.1"",
        ""category"": ""Observation""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Evaluable disease""
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""RECIST 1.1""
    }
]
```"
NCT02836548,Inclusion: Minimal acceptable safety laboratory values,"```json
[]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Type 2 diabetes mellitus""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""Metformin""
    },
    {
        ""id"": 3,
        ""type"": ""Measurement"",
        ""name"": ""Serum creatinine""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""Chemotherapy""
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""Smoking""
    },
    {
        ""id"": 6,
        ""type"": ""Observation"",
        ""name"": ""30 to 75 years old"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 30,
                ""upper_bound"": 75,
                ""unit"": ""years""
            }
        }
    }
]
```"
NCT02836548,Inclusion: Negative pregnancy test (urine/serum) within 72 hours before receiving the first dose of study medication for female patients with childbearing potential;,"```json
[
    {
        ""entity"": ""Negative"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""pregnancy test (urine/serum)"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""within 72 hours"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""before receiving the first dose of study medication"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""female patients with childbearing potential"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""female patients with childbearing potential""
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""pregnancy test (urine/serum)"",
        ""value"": {
            ""qualitative"": ""Negative""
        },
        ""temporal"": {
            ""start"": {
                ""number"": 72,
                ""unit"": ""hours""
            },
            ""end"": {
                ""number"": 0,
                ""unit"": ""hours""
            },
            ""reference_event"": 3
        }
    },
    {
        ""id"": 3,
        ""type"": ""Procedure/Device"",
        ""name"": ""receiving the first dose of study medication""
    }
]
```"
NCT02836548,"Inclusion: Able and willing to undergo fresh histological tumor sampling prior to start, upon treatment and upon progression of vorinostat.","```json
[
    {
        ""entity"": ""Able and willing"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""fresh histological tumor sampling"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""prior to start"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""upon treatment"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""upon progression"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""vorinostat"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Able and willing""
    },
    {
        ""id"": 2,
        ""type"": ""Procedure/Device"",
        ""name"": ""fresh histological tumor sampling"",
        ""temporal"": {
            ""start"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""end"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""reference_event"": 1
        }
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""vorinostat""
    }
]
```"
NCT02836548,"Exclusion: Any treatment with investigational drugs, except BRAFi and MEKi, within 28 days prior to receiving the first dose of investigational treatment; or 21 days for standard chemotherapy and immunotherapy;","```json
[
    {
        ""entity"": ""treatment with investigational drugs"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""BRAFi"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""MEKi"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""within 28 days"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""prior to receiving the first dose of investigational treatment"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""21 days"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""standard chemotherapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""immunotherapy"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Drug/Substance"",
        ""name"": ""treatment with investigational drugs"",
        ""temporal"": {
            ""start"": {
                ""number"": 28,
                ""unit"": ""days""
            },
            ""reference_event"": 2
        }
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""BRAFi"",
        ""temporal"": {
            ""start"": {
                ""number"": 28,
                ""unit"": ""days""
            },
            ""reference_event"": 3
        }
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""MEKi"",
        ""temporal"": {
            ""start"": {
                ""number"": 28,
                ""unit"": ""days""
            },
            ""reference_event"": 4
        }
    },
    {
        ""id"": 4,
        ""type"": ""Drug/Substance"",
        ""name"": ""standard chemotherapy"",
        ""temporal"": {
            ""start"": {
                ""number"": 21,
                ""unit"": ""days""
            },
            ""reference_event"": 5
        }
    },
    {
        ""id"": 5,
        ""type"": ""Drug/Substance"",
        ""name"": ""immunotherapy"",
        ""temporal"": {
            ""start"": {
                ""number"": 21,
                ""unit"": ""days""
            },
            ""reference_event"": 6
        }
    }
]
```"
NCT02836548,Exclusion: Patients who have had previous treatment with vorinostat or other HDAC inhibitors;,"```json
[
    {
        ""entity"": ""previous treatment"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""vorinostat"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""HDAC inhibitors"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Procedure/Device"",
        ""name"": ""previous treatment""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""vorinostat""
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""HDAC inhibitors""
    }
]
```"
NCT02836548,Exclusion: Leptomeningeal disease;,"```json
[
    {
        ""entity"": ""Leptomeningeal disease"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Leptomeningeal disease""
    }
]
```"
NCT02836548,Exclusion: Symptomatic brain metastasis. Patients previously treated or untreated for the condition and/or who are asymptomatic in the absence of corticosteroid therapy are allowed to enroll. Patients are not permitted to receive enzyme inducing anti-epileptic drugs or corticosteroids;,"```json
[
    {
        ""entity"": ""Symptomatic brain metastasis"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""previously treated"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""untreated"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""condition"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""asymptomatic"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""absence of corticosteroid therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""enzyme inducing anti-epileptic drugs"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""corticosteroids"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Symptomatic brain metastasis""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""condition""
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""absence of corticosteroid therapy""
    },
    {
        ""id"": 4,
        ""type"": ""Drug/Substance"",
        ""name"": ""enzyme inducing anti-epileptic drugs""
    },
    {
        ""id"": 5,
        ""type"": ""Drug/Substance"",
        ""name"": ""corticosteroids""
    }
]
```"
NCT02836548,Exclusion: Clinical progression of melanoma in the first week of discontinuation of BRAFi or BRAFi/MEKi;,"```json
[
    {
        ""entity"": ""Clinical progression of melanoma"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""first week"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""discontinuation of BRAFi or BRAFi/MEKi"",
        ""category"": ""Procedure/Device""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Clinical progression of melanoma""
    },
    {
        ""id"": 2,
        ""type"": ""Procedure/Device"",
        ""name"": ""discontinuation of BRAFi or BRAFi/MEKi"",
        ""temporal"": {
            ""start"": {
                ""number"": 1,
                ""unit"": ""week""
            },
            ""reference_event"": 1
        }
    }
]
```"
NCT02836548,Exclusion: Woman who are pregnant or breast feeding;,"```json
[
    {
        ""entity"": ""pregnant"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""breast feeding"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""pregnant""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""breast feeding""
    }
]
```"
NCT02836548,"Exclusion: Unreliable contraceptive methods. Both men and women enrolled in this trial must agree to use a reliable contraceptive method from screening until 30 days after the last dose of study medication (adequate contraceptive methods are: oral or injected or implanted hormonal methods of contraception, condom, sterilization, other barrier contraceptive measures preferably in combination with condoms, true abstinence);","```json
[]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Type 2 diabetes mellitus""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""Metformin""
    },
    {
        ""id"": 3,
        ""type"": ""Measurement"",
        ""name"": ""Serum creatinine""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""Chemotherapy""
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""Smoking""
    },
    {
        ""id"": 6,
        ""type"": ""Observation"",
        ""name"": ""30 to 75 years old"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 30,
                ""upper_bound"": 75,
                ""unit"": ""years""
            }
        }
    }
]
```"
NCT02836548,Exclusion: Radiotherapy within the last 4 weeks prior to receiving the first dose of investigational treatment; except 1x8 Gray for pain palliation;,"```json
[
    {
        ""entity"": ""Radiotherapy"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""within the last 4 weeks"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""prior to receiving the first dose of investigational treatment"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""1x8 Gray"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""pain palliation"",
        ""category"": ""Procedure/Device""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Procedure/Device"",
        ""name"": ""Radiotherapy"",
        ""temporal"": {
            ""start"": {
                ""number"": 4,
                ""unit"": ""weeks""
            },
            ""reference_event"": ""prior to receiving the first dose of investigational treatment""
        }
    },
    {
        ""id"": 2,
        ""type"": ""Procedure/Device"",
        ""name"": ""pain palliation"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 1,
                ""upper_bound"": 8,
                ""unit"": ""Gray""
            }
        }
    }
]
```"
NCT02836548,Exclusion: Uncontrolled infectious disease or known Human Immunodeficiency Virus HIV-1 or HIV-2 type patients;,"```json
[
    {
        ""entity"": ""Uncontrolled infectious disease"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""known Human Immunodeficiency Virus HIV-1 or HIV-2"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Uncontrolled infectious disease""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""known Human Immunodeficiency Virus HIV-1 or HIV-2""
    }
]
```"
NCT02836548,Exclusion: Patients with a known history of hepatitis B or C;,"```json
[
    {
        ""entity"": ""known history"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""hepatitis B"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""hepatitis C"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""hepatitis B""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""hepatitis C""
    }
]
```"
NCT02836548,Exclusion: Recent myocardial infarction (\< 6 months before receiving the first dose of study medication) or unstable angina;,"```json
[
    {
        ""entity"": ""Recent myocardial infarction"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""< 6 months"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""before receiving the first dose of study medication"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""unstable angina"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Recent myocardial infarction"",
        ""temporal"": {
            ""start"": {
                ""number"": 6,
                ""unit"": ""months""
            },
            ""reference_event"": ""receiving the first dose of study medication""
        }
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""unstable angina""
    }
]
```"
NCT04526730,"Inclusion: Participant must be ≥ 18 years of age inclusive, at the time of signing the informed consent","```json
[
    {
        ""entity"": ""≥ 18 years"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""age"",
        ""category"": ""Observation""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""age"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 18,
                ""unit"": ""years""
            }
        }
    }
]
```"
NCT04526730,Inclusion: Histologic diagnosis of melanoma,"```json
[
    {
        ""entity"": ""Histologic diagnosis"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""melanoma"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Histologic diagnosis""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""melanoma""
    }
]
```"
NCT04526730,Inclusion: Must be considered surgically operable and may present as any of the following groups:,"```json
[]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Type 2 diabetes mellitus""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""Metformin""
    },
    {
        ""id"": 3,
        ""type"": ""Measurement"",
        ""name"": ""Serum creatinine""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""Chemotherapy""
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""Smoking""
    },
    {
        ""id"": 6,
        ""type"": ""Observation"",
        ""name"": ""30 to 75 years old"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 30,
                ""upper_bound"": 75,
                ""unit"": ""years""
            }
        }
    }
]
```"
NCT04526730,"Inclusion: Participants are eligible for this study either at presentation for primary melanoma with concurrent regional nodal and/or in-transit or distant metastasis, or at the time of clinically detected nodal, in transit, or distant recurrence","```json
[
    {
        ""entity"": ""primary melanoma"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""concurrent regional nodal metastasis"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""in-transit metastasis"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""distant metastasis"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""clinically detected nodal recurrence"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""in transit recurrence"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""distant recurrence"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""primary melanoma""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""concurrent regional nodal metastasis""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""in-transit metastasis""
    },
    {
        ""id"": 4,
        ""type"": ""Condition"",
        ""name"": ""distant metastasis""
    },
    {
        ""id"": 5,
        ""type"": ""Condition"",
        ""name"": ""clinically detected nodal recurrence""
    },
    {
        ""id"": 6,
        ""type"": ""Condition"",
        ""name"": ""in transit recurrence""
    },
    {
        ""id"": 7,
        ""type"": ""Condition"",
        ""name"": ""distant recurrence""
    }
]
```"
NCT04526730,"Inclusion: Participants must be evaluated by standard-of-care full body imaging studies including positron emission tomography - computed tomography (PET-CT ;preferred; including diagnostic CT component if possible) or CT (if PET-CT cannot be done) as well as magnetic resonance imaging (MRI) of the brain (or CT if MRI cannot be done) as part of the initial clinical work-up at Screening (no more than 4 weeks prior to Cycle 1, Day 1).","```json
[
    {
        ""entity"": ""standard-of-care full body imaging studies"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""positron emission tomography - computed tomography (PET-CT)"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""diagnostic CT component"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""CT"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""magnetic resonance imaging (MRI) of the brain"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""CT"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""no more than 4 weeks prior to Cycle 1, Day 1"",
        ""category"": ""Temporal Constraints""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Procedure/Device"",
        ""name"": ""standard-of-care full body imaging studies""
    },
    {
        ""id"": 2,
        ""type"": ""Procedure/Device"",
        ""name"": ""positron emission tomography - computed tomography (PET-CT)""
    },
    {
        ""id"": 3,
        ""type"": ""Procedure/Device"",
        ""name"": ""diagnostic CT component""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""CT""
    },
    {
        ""id"": 5,
        ""type"": ""Procedure/Device"",
        ""name"": ""magnetic resonance imaging (MRI) of the brain""
    },
    {
        ""id"": 6,
        ""type"": ""Procedure/Device"",
        ""name"": ""CT"",
        ""temporal"": {
            ""start"": {
                ""number"": 4,
                ""unit"": ""weeks""
            },
            ""reference_event"": 1
        }
    }
]
```"
NCT04526730,"Inclusion: Have measurable disease based on RECIST v1.1, with at least one anatomically distinct lesion. Lesion or lesions must meet all the following baseline criteria:","```json
[
    {
        ""entity"": ""measurable disease"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""RECIST v1.1"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""at least one anatomically distinct lesion"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""Lesion"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""lesions"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""baseline criteria"",
        ""category"": ""Observation""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""measurable disease""
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""RECIST v1.1""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""at least one anatomically distinct lesion"",
        ""occurrence"": {
            ""operator"": ""at least"",
            ""number"": 1
        }
    },
    {
        ""id"": 4,
        ""type"": ""Condition"",
        ""name"": ""Lesion""
    },
    {
        ""id"": 5,
        ""type"": ""Condition"",
        ""name"": ""lesions""
    },
    {
        ""id"": 6,
        ""type"": ""Observation"",
        ""name"": ""baseline criteria""
    }
]
```"
NCT04526730,Inclusion: Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.,"```json
[]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Type 2 diabetes mellitus""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""Metformin""
    },
    {
        ""id"": 3,
        ""type"": ""Measurement"",
        ""name"": ""Serum creatinine""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""Chemotherapy""
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""Smoking""
    },
    {
        ""id"": 6,
        ""type"": ""Observation"",
        ""name"": ""30 to 75 years old"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 30,
                ""upper_bound"": 75,
                ""unit"": ""years""
            }
        }
    }
]
```"
NCT04526730,"Inclusion: Male Participants: Male subjects of childbearing potential must be surgically sterile, or must agree to use adequate method of contraception during the study and at least 5 months following the last day of study drug administration. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject","```json
[]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Type 2 diabetes mellitus""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""Metformin""
    },
    {
        ""id"": 3,
        ""type"": ""Measurement"",
        ""name"": ""Serum creatinine""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""Chemotherapy""
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""Smoking""
    },
    {
        ""id"": 6,
        ""type"": ""Observation"",
        ""name"": ""30 to 75 years old"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 30,
                ""upper_bound"": 75,
                ""unit"": ""years""
            }
        }
    }
]
```"
NCT04526730,"Inclusion: Female participants: Women of childbearing potential must have negative serum or urine pregnancy test within 72 hours prior to receiving the first study drug administration. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. For women of childbearing potential, must be willing to use an adequate method of contraception from 30 days prior to the first study drug administration and 5 months following last day study drug administration (either tavo or nivolumab); acceptable methods include hormonal contraception (oral contraceptives - as long as on stable dose, patch, implant, and injection), intrauterine devices, or double barrier methods (e.g. vaginal diaphragm/vaginal sponge plus condom, or condom plus spermicidal jelly), sexual abstinence or a vasectomized partner. Women may be surgically sterile or at least 1-year post-last menstrual period. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.","```json
[
    {
        ""entity"": ""Female participants"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""Women of childbearing potential"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""negative serum or urine pregnancy test"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""within 72 hours prior to receiving the first study drug administration"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""positive"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""serum pregnancy test"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""Women of childbearing potential"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""30 days prior to the first study drug administration"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""5 months following last day study drug administration"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""tavo"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""nivolumab"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""hormonal contraception"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""oral contraceptives"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""stable dose"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""patch"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""implant"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""injection"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""intrauterine devices"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""double barrier methods"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""vaginal diaphragm"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""vaginal sponge"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""condom"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""spermicidal jelly"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""sexual abstinence"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""vasectomized partner"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""surgically sterile"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""at least 1-year post-last menstrual period"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""Abstinence"",
        ""category"": ""Observation""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Female participants""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""Women of childbearing potential""
    },
    {
        ""id"": 3,
        ""type"": ""Observation"",
        ""name"": ""negative serum or urine pregnancy test"",
        ""temporal"": {
            ""start"": {
                ""number"": 72,
                ""unit"": ""hours""
            },
            ""reference_event"": 4
        }
    },
    {
        ""id"": 4,
        ""type"": ""Observation"",
        ""name"": ""serum pregnancy test"",
        ""value"": {
            ""qualitative"": ""positive""
        }
    },
    {
        ""id"": 5,
        ""type"": ""Condition"",
        ""name"": ""Women of childbearing potential"",
        ""temporal"": {
            ""start"": {
                ""number"": 30,
                ""unit"": ""days""
            },
            ""reference_event"": 6
        }
    },
    {
        ""id"": 6,
        ""type"": ""Condition"",
        ""name"": ""Women of childbearing potential"",
        ""temporal"": {
            ""end"": {
                ""number"": 5,
                ""unit"": ""months""
            },
            ""reference_event"": 7
        }
    },
    {
        ""id"": 7,
        ""type"": ""Drug/Substance"",
        ""name"": ""tavo""
    },
    {
        ""id"": 8,
        ""type"": ""Drug/Substance"",
        ""name"": ""nivolumab""
    },
    {
        ""id"": 9,
        ""type"": ""Drug/Substance"",
        ""name"": ""hormonal contraception""
    },
    {
        ""id"": 10,
        ""type"": ""Drug/Substance"",
        ""name"": ""oral contraceptives"",
        ""value"": {
            ""qualitative"": ""stable dose""
        }
    },
    {
        ""id"": 11,
        ""type"": ""Drug/Substance"",
        ""name"": ""patch""
    },
    {
        ""id"": 12,
        ""type"": ""Drug/Substance"",
        ""name"": ""implant""
    },
    {
        ""id"": 13,
        ""type"": ""Drug/Substance"",
        ""name"": ""injection""
    },
    {
        ""id"": 14,
        ""type"": ""Drug/Substance"",
        ""name"": ""intrauterine devices""
    },
    {
        ""id"": 15,
        ""type"": ""Drug/Substance"",
        ""name"": ""double barrier methods""
    },
    {
        ""id"": 16,
        ""type"": ""Drug/Substance"",
        ""name"": ""vaginal diaphragm""
    },
    {
        ""id"": 17,
        ""type"": ""Drug/Substance"",
        ""name"": ""vaginal sponge""
    },
    {
        ""id"": 18,
        ""type"": ""Drug/Substance"",
        ""name"": ""condom""
    },
    {
        ""id"": 19,
        ""type"": ""Drug/Substance"",
        ""name"": ""spermicidal jelly""
    },
    {
        ""id"": 20,
        ""type"": ""Observation"",
        ""name"": ""sexual abstinence""
    },
    {
        ""id"": 21,
        ""type"": ""Observation"",
        ""name"": ""vasectomized partner""
    },
    {
        ""id"": 22,
        ""type"": ""Condition"",
        ""name"": ""surgically sterile"",
        ""temporal"": {
            ""start"": {
                ""number"": 1,
                ""unit"": ""year""
            },
            ""reference_event"": 23
        }
    },
    {
        ""id"": 23,
        ""type"": ""Observation"",
        ""name"": ""Abstinence""
    }
]
```"
NCT04526730,Inclusion: Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol,"```json
[]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Type 2 diabetes mellitus""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""Metformin""
    },
    {
        ""id"": 3,
        ""type"": ""Measurement"",
        ""name"": ""Serum creatinine""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""Chemotherapy""
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""Smoking""
    },
    {
        ""id"": 6,
        ""type"": ""Observation"",
        ""name"": ""30 to 75 years old"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 30,
                ""upper_bound"": 75,
                ""unit"": ""years""
            }
        }
    }
]
```"
NCT04526730,"Exclusion: Participant has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. Also, includes patients who are considered disease-free for at least 3 years from the last definitive treatment for a second malignancy.","```json
[
    {
        ""entity"": ""known additional malignancy"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""progressing"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""requires active treatment"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""basal cell carcinoma of the skin"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""squamous cell carcinoma of the skin"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""potentially curative therapy"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""in situ cervical cancer"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""disease-free"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""at least 3 years"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""last definitive treatment"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""second malignancy"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""known additional malignancy""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""basal cell carcinoma of the skin""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""squamous cell carcinoma of the skin""
    },
    {
        ""id"": 4,
        ""type"": ""Condition"",
        ""name"": ""in situ cervical cancer""
    },
    {
        ""id"": 5,
        ""type"": ""Procedure/Device"",
        ""name"": ""potentially curative therapy""
    },
    {
        ""id"": 6,
        ""type"": ""Procedure/Device"",
        ""name"": ""last definitive treatment""
    },
    {
        ""id"": 7,
        ""type"": ""Condition"",
        ""name"": ""second malignancy"",
        ""temporal"": {
            ""start"": {
                ""number"": 3,
                ""unit"": ""years""
            },
            ""reference_event"": 6
        }
    }
]
```"
NCT04526730,Exclusion: Participants who have Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies at Screening). HIV testing at screening is not required unless considered clinically indicated by the treating physician.,"```json
[
    {
        ""entity"": ""Human Immunodeficiency Virus (HIV)"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""HIV 1/2 antibodies"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""Screening"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""HIV testing"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""screening"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""clinically indicated"",
        ""category"": ""Qualifiers/Modifiers""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Human Immunodeficiency Virus (HIV)""
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""HIV 1/2 antibodies""
    },
    {
        ""id"": 3,
        ""type"": ""Observation"",
        ""name"": ""HIV testing"",
        ""temporal"": {
            ""start"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""end"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""reference_event"": 4
        }
    }
]
```"
NCT04526730,"Exclusion: Participants who have active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \[qualitative\] is detected at Screening); Note: Participants who have been vaccinated against Hepatitis B and who are positive only for the Hepatitis B surface antibody are permitted to participate in the study. Hepatitis B and C testing at screening is not required unless considered clinically indicated by the treating physician.","```json
[
    {
        ""entity"": ""active Hepatitis B"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""HBsAg reactive"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""Hepatitis C"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""HCV RNA [qualitative] is detected"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""Screening"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""Hepatitis B surface antibody"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""Hepatitis B and C testing"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""screening"",
        ""category"": ""Temporal Constraints""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""active Hepatitis B""
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""HBsAg reactive""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""Hepatitis C""
    },
    {
        ""id"": 4,
        ""type"": ""Observation"",
        ""name"": ""HCV RNA [qualitative] is detected""
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""Hepatitis B surface antibody""
    },
    {
        ""id"": 6,
        ""type"": ""Observation"",
        ""name"": ""Hepatitis B and C testing""
    }
]
```"
NCT04526730,Exclusion: Participant has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug. The use of physiologic doses of corticosteroids may be approved after consultation with the Principal Investigator.,"```json
[
    {
        ""entity"": ""diagnosis of immunodeficiency"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""systemic steroid therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""immunosuppressive therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""within 7 days prior to the first dose of study drug"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""physiologic doses of corticosteroids"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""diagnosis of immunodeficiency""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""systemic steroid therapy"",
        ""temporal"": {
            ""start"": {
                ""number"": 7,
                ""unit"": ""days""
            },
            ""reference_event"": 3
        }
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""immunosuppressive therapy"",
        ""temporal"": {
            ""start"": {
                ""number"": 7,
                ""unit"": ""days""
            },
            ""reference_event"": 2
        }
    },
    {
        ""id"": 4,
        ""type"": ""Drug/Substance"",
        ""name"": ""physiologic doses of corticosteroids""
    }
]
```"
NCT04526730,Exclusion: Participant has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.,"```json
[
    {
        ""entity"": ""history of (non-infectious) pneumonitis"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""required steroids"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""current pneumonitis"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""history of (non-infectious) pneumonitis""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""required steroids""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""current pneumonitis""
    }
]
```"
NCT04526730,Exclusion: Participant has a history of interstitial lung disease.,"```json
[
    {
        ""entity"": ""history of interstitial lung disease"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""history of interstitial lung disease""
    }
]
```"
NCT04526730,Exclusion: Participant has an active infection requiring systemic therapy.,"```json
[
    {
        ""entity"": ""active infection"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""requiring systemic therapy"",
        ""category"": ""Qualifier/Modifier""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""active infection"",
        ""occurrence"": {
            ""operator"": ""at least"",
            ""number"": 1
        }
    }
]
```"
NCT04526730,"Exclusion: Participant has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.","```json
[
    {
        ""entity"": ""history"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""current evidence"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""condition"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""laboratory abnormality"",
        ""category"": ""Observation""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""history""
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""current evidence""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""condition""
    },
    {
        ""id"": 4,
        ""type"": ""Drug/Substance"",
        ""name"": ""therapy""
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""laboratory abnormality""
    }
]
```"
NCT04526730,"Exclusion: Participant has not recovered (i.e., \> Grade 1 at Cycle 1, Day 1) from AEs due to a previously administered agent.","```json
[
    {
        ""entity"": ""not recovered"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""> Grade 1"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""Cycle 1, Day 1"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""AEs"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""previously administered agent"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""not recovered""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""AEs""
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""previously administered agent""
    }
]
```"
NCT04526730,Exclusion: Participant has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.,"```json
[
    {
        ""entity"": ""psychiatric disorders"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""substance abuse disorders"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""psychiatric disorders""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""substance abuse disorders""
    }
]
```"
NCT04526730,"Exclusion: Participants who are pregnant or breast feeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 5 months after the last dose of trial treatment.","```json
[
    {
        ""entity"": ""pregnant"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""breast feeding"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""expecting to conceive or father children"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""within the projected duration of the trial"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""starting with the screening visit through 5 months after the last dose of trial treatment"",
        ""category"": ""Temporal Constraints""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""pregnant""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""breast feeding""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""expecting to conceive or father children"",
        ""temporal"": {
            ""start"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""end"": {
                ""number"": 5,
                ""unit"": ""months""
            },
            ""reference_event"": 4
        }
    },
    {
        ""id"": 4,
        ""type"": ""Observation"",
        ""name"": ""screening visit""
    }
]
```"
NCT04526730,Exclusion: Participants with electronic pacemakers or defibrillators,"```json
[
    {
        ""entity"": ""electronic pacemakers"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""defibrillators"",
        ""category"": ""Procedure/Device""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Procedure/Device"",
        ""name"": ""electronic pacemakers""
    },
    {
        ""id"": 2,
        ""type"": ""Procedure/Device"",
        ""name"": ""defibrillators""
    }
]
```"
NCT04526730,Exclusion: Participants who have received a live-virus vaccination within 30 days of the first dose of treatment. Seasonal flu vaccines that do not contain live virus are permitted,"```json
[
    {
        ""entity"": ""live-virus vaccination"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""within 30 days"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""first dose of treatment"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""Seasonal flu vaccines"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""do not contain live virus"",
        ""category"": ""Qualifiers/Modifiers""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Drug/Substance"",
        ""name"": ""live-virus vaccination"",
        ""temporal"": {
            ""start"": {
                ""number"": 30,
                ""unit"": ""days""
            },
            ""reference_event"": 2
        }
    },
    {
        ""id"": 2,
        ""type"": ""Procedure/Device"",
        ""name"": ""first dose of treatment""
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""Seasonal flu vaccines"",
        ""value"": {
            ""qualitative"": ""do not contain live virus""
        }
    }
]
```"
NCT04526730,"Exclusion: Participants who have received transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors (including G-CSF, GM-CSF or recombinant erythropoietin) within 4 weeks prior to study Cycle 1, Day 1.","```json
[
    {
        ""entity"": ""transfusion of blood products"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""platelets"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""red blood cells"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""administration of colony stimulating factors"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""G-CSF"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""GM-CSF"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""recombinant erythropoietin"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""within 4 weeks"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""prior to study Cycle 1, Day 1"",
        ""category"": ""Temporal Constraints""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Procedure/Device"",
        ""name"": ""transfusion of blood products"",
        ""temporal"": {
            ""start"": {
                ""number"": 4,
                ""unit"": ""weeks""
            },
            ""reference_event"": ""study Cycle 1, Day 1""
        }
    },
    {
        ""id"": 2,
        ""type"": ""Procedure/Device"",
        ""name"": ""platelets"",
        ""temporal"": {
            ""start"": {
                ""number"": 4,
                ""unit"": ""weeks""
            },
            ""reference_event"": ""study Cycle 1, Day 1""
        }
    },
    {
        ""id"": 3,
        ""type"": ""Procedure/Device"",
        ""name"": ""red blood cells"",
        ""temporal"": {
            ""start"": {
                ""number"": 4,
                ""unit"": ""weeks""
            },
            ""reference_event"": ""study Cycle 1, Day 1""
        }
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""administration of colony stimulating factors"",
        ""temporal"": {
            ""start"": {
                ""number"": 4,
                ""unit"": ""weeks""
            },
            ""reference_event"": ""study Cycle 1, Day 1""
        }
    },
    {
        ""id"": 5,
        ""type"": ""Procedure/Device"",
        ""name"": ""G-CSF"",
        ""temporal"": {
            ""start"": {
                ""number"": 4,
                ""unit"": ""weeks""
            },
            ""reference_event"": ""study Cycle 1, Day 1""
        }
    },
    {
        ""id"": 6,
        ""type"": ""Procedure/Device"",
        ""name"": ""GM-CSF"",
        ""temporal"": {
            ""start"": {
                ""number"": 4,
                ""unit"": ""weeks""
            },
            ""reference_event"": ""study Cycle 1, Day 1""
        }
    },
    {
        ""id"": 7,
        ""type"": ""Procedure/Device"",
        ""name"": ""recombinant erythropoietin"",
        ""temporal"": {
            ""start"": {
                ""number"": 4,
                ""unit"": ""weeks""
            },
            ""reference_event"": ""study Cycle 1, Day 1""
        }
    }
]
```"
NCT04526730,Exclusion: Previous treatment with anti-PD1 or anti-PDL1 immunotherapy.,"```json
[
    {
        ""entity"": ""Previous"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""treatment"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""anti-PD1 immunotherapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""anti-PDL1 immunotherapy"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Procedure/Device"",
        ""name"": ""treatment"",
        ""temporal"": {
            ""start"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""end"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""reference_event"": 0
        }
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""anti-PD1 immunotherapy"",
        ""temporal"": {
            ""start"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""end"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""reference_event"": 0
        }
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""anti-PDL1 immunotherapy"",
        ""temporal"": {
            ""start"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""end"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""reference_event"": 0
        }
    }
]
```"
NCT04526730,"Exclusion: Participation in another clinical study and systemic therapy within 30 days of Cycle 1, Day 1.","```json
[
    {
        ""entity"": ""Participation in another clinical study"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""systemic therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""within 30 days"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""Cycle 1, Day 1"",
        ""category"": ""Temporal Constraints""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Participation in another clinical study"",
        ""temporal"": {
            ""start"": {
                ""number"": 30,
                ""unit"": ""days""
            },
            ""reference_event"": 2
        }
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""systemic therapy"",
        ""temporal"": {
            ""start"": {
                ""number"": 1,
                ""unit"": ""days""
            },
            ""reference_event"": 3
        }
    },
    {
        ""id"": 3,
        ""type"": ""Observation"",
        ""name"": ""Cycle 1, Day 1""
    }
]
```"
NCT04526730,Exclusion: ECOG Performance Status: \>1,"```json
[
    {
        ""entity"": ""ECOG Performance Status"",
        ""category"": ""Observation""
    },
    {
        ""entity"": "">1"",
        ""category"": ""Measurement""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""ECOG Performance Status"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 1,
                ""upper_bound"": null,
                ""unit"": null
            }
        }
    }
]
```"
NCT04526730,Exclusion: Inadequate organ function as defined per protocol,"```json
[
    {
        ""entity"": ""Inadequate organ function"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Inadequate organ function""
    }
]
```"
NCT04526730,Exclusion: Participant has severe hypersensitivity (≥Grade 3) to nivolumab and/or any of its excipients,"```json
[
    {
        ""entity"": ""severe"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""hypersensitivity"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""≥Grade 3"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""nivolumab"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""excipients"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""hypersensitivity"",
        ""occurrence"": {
            ""operator"": ""at least"",
            ""number"": 1
        },
        ""value"": {
            ""qualitative"": ""severe""
        }
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""nivolumab""
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""excipients""
    }
]
```"
NCT03071757,"Inclusion: Participants must have histologic or cytology diagnosis of a known immunogenic solid tumor, as described for Part 1 Dose Escalation and Part 2 Cohort Expansion:","```json
[
    {
        ""entity"": ""histologic or cytology diagnosis"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""immunogenic solid tumor"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""Part 1 Dose Escalation"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""Part 2 Cohort Expansion"",
        ""category"": ""Procedure/Device""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""histologic or cytology diagnosis""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""immunogenic solid tumor""
    },
    {
        ""id"": 3,
        ""type"": ""Procedure/Device"",
        ""name"": ""Part 1 Dose Escalation""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""Part 2 Cohort Expansion""
    }
]
```"
NCT03071757,Inclusion: Part 1 Dose Escalation:,"```json
[]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Type 2 diabetes mellitus""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""Metformin""
    },
    {
        ""id"": 3,
        ""type"": ""Measurement"",
        ""name"": ""Serum creatinine""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""Chemotherapy""
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""Smoking""
    },
    {
        ""id"": 6,
        ""type"": ""Observation"",
        ""name"": ""30 to 75 years old"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 30,
                ""upper_bound"": 75,
                ""unit"": ""years""
            }
        }
    }
]
```"
NCT03071757,"Inclusion: Participants with advanced or metastatic solid tumors that have exhausted standard treatment for their incurable disease and for whom there is currently no programmed cell death 1 (PD-1)/ programmed cell death-ligand 1 (PD-L1) approved therapy, with immunogenic type tumors such as, but not limited to triple negative breast cancer (TNBC), ovarian cancer, small cell lung cancer, mesothelioma, and cholangiocarcinoma.","```json
[
    {
        ""entity"": ""advanced or metastatic solid tumors"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""exhausted standard treatment"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""incurable disease"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""no programmed cell death 1 (PD-1)/ programmed cell death-ligand 1 (PD-L1) approved therapy"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""immunogenic type tumors"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""triple negative breast cancer (TNBC)"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""ovarian cancer"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""small cell lung cancer"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""mesothelioma"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""cholangiocarcinoma"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""advanced or metastatic solid tumors""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""exhausted standard treatment""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""incurable disease""
    },
    {
        ""id"": 4,
        ""type"": ""Condition"",
        ""name"": ""no programmed cell death 1 (PD-1)/ programmed cell death-ligand 1 (PD-L1) approved therapy""
    },
    {
        ""id"": 5,
        ""type"": ""Condition"",
        ""name"": ""immunogenic type tumors""
    },
    {
        ""id"": 6,
        ""type"": ""Condition"",
        ""name"": ""triple negative breast cancer (TNBC)""
    },
    {
        ""id"": 7,
        ""type"": ""Condition"",
        ""name"": ""ovarian cancer""
    },
    {
        ""id"": 8,
        ""type"": ""Condition"",
        ""name"": ""small cell lung cancer""
    },
    {
        ""id"": 9,
        ""type"": ""Condition"",
        ""name"": ""mesothelioma""
    },
    {
        ""id"": 10,
        ""type"": ""Condition"",
        ""name"": ""cholangiocarcinoma""
    }
]
```"
NCT03071757,"Inclusion: Participants who are refractory to a PD-1/PD-L1 agent, with tumor types such as melanoma, NSCLC, platinum-pretreated head and neck cancer, second line bladder and RCC.","```json
[
    {
        ""entity"": ""refractory"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""PD-1/PD-L1 agent"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""tumor types"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""melanoma"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""NSCLC"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""platinum-pretreated head and neck cancer"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""second line bladder"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""RCC"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""tumor types""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""melanoma""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""NSCLC""
    },
    {
        ""id"": 4,
        ""type"": ""Condition"",
        ""name"": ""platinum-pretreated head and neck cancer""
    },
    {
        ""id"": 5,
        ""type"": ""Condition"",
        ""name"": ""second line bladder""
    },
    {
        ""id"": 6,
        ""type"": ""Condition"",
        ""name"": ""RCC""
    },
    {
        ""id"": 7,
        ""type"": ""Drug/Substance"",
        ""name"": ""PD-1/PD-L1 agent""
    }
]
```"
NCT03071757,Inclusion: Part 2A and 2B Cohort Expansion:,"```json
[]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Type 2 diabetes mellitus""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""Metformin""
    },
    {
        ""id"": 3,
        ""type"": ""Measurement"",
        ""name"": ""Serum creatinine""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""Chemotherapy""
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""Smoking""
    },
    {
        ""id"": 6,
        ""type"": ""Observation"",
        ""name"": ""30 to 75 years old"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 30,
                ""upper_bound"": 75,
                ""unit"": ""years""
            }
        }
    }
]
```"
NCT03071757,Inclusion: 2A : TNBC ABBV-368 monotherapy cohorts: Subjects with locally advanced or metastatic TNBC that have exhausted standard treatment for their incurable disease.,"```json
[
    {
        ""entity"": ""locally advanced or metastatic TNBC"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""exhausted standard treatment"",
        ""category"": ""Qualifier/Modifier""
    },
    {
        ""entity"": ""incurable disease"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""locally advanced or metastatic TNBC""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""incurable disease""
    }
]
```"
NCT03071757,"Inclusion: 2B : Head and Neck cohort: Participants with recurrent squamous cell head and neck carcinoma that are not candidates for curative treatment with local or systemic therapy, or metastatic (disseminated) head and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx that is considered incurable by local therapies.","```json
[
    {
        ""entity"": ""recurrent squamous cell head and neck carcinoma"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""curative treatment with local or systemic therapy"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""metastatic (disseminated) head and neck squamous cell carcinoma"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""oral cavity"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""oropharynx"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""hypopharynx"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""larynx"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""incurable by local therapies"",
        ""category"": ""Qualifier/Modifier""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""recurrent squamous cell head and neck carcinoma""
    },
    {
        ""id"": 2,
        ""type"": ""Procedure/Device"",
        ""name"": ""curative treatment with local or systemic therapy""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""metastatic (disseminated) head and neck squamous cell carcinoma""
    },
    {
        ""id"": 4,
        ""type"": ""Condition"",
        ""name"": ""oral cavity""
    },
    {
        ""id"": 5,
        ""type"": ""Condition"",
        ""name"": ""oropharynx""
    },
    {
        ""id"": 6,
        ""type"": ""Condition"",
        ""name"": ""hypopharynx""
    },
    {
        ""id"": 7,
        ""type"": ""Condition"",
        ""name"": ""larynx""
    }
]
```"
NCT03071757,Inclusion: Part 3A and 3B Imaging Substudy:,"```json
[]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Type 2 diabetes mellitus""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""Metformin""
    },
    {
        ""id"": 3,
        ""type"": ""Measurement"",
        ""name"": ""Serum creatinine""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""Chemotherapy""
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""Smoking""
    },
    {
        ""id"": 6,
        ""type"": ""Observation"",
        ""name"": ""30 to 75 years old"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 30,
                ""upper_bound"": 75,
                ""unit"": ""years""
            }
        }
    }
]
```"
NCT03071757,Inclusion: 3A: Participants with locally advanced or metastatic TNBC that have exhausted standard treatment for their incurable disease and are treatment naïve to a PD-1/PD-L1 targeting agent.,"```json
[
    {
        ""entity"": ""locally advanced or metastatic TNBC"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""exhausted standard treatment"",
        ""category"": ""Qualifier/Modifier""
    },
    {
        ""entity"": ""incurable disease"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""treatment naïve"",
        ""category"": ""Qualifier/Modifier""
    },
    {
        ""entity"": ""PD-1/PD-L1 targeting agent"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""locally advanced or metastatic TNBC""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""incurable disease""
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""PD-1/PD-L1 targeting agent""
    }
]
```"
NCT03071757,"Inclusion: 3B: Participants with recurrent HNSCC that are not candidates for curative treatment with local or systemic therapy, or metastatic HNSCC of the oral cavity, oropharynx, hypopharynx, and larynx that is considered incurable by local therapies. Participants must be treatment naïve to a PD-1/PD-L1 targeting agent.","```json
[
    {
        ""entity"": ""recurrent HNSCC"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""curative treatment"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""local therapy"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""systemic therapy"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""metastatic HNSCC"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""oral cavity"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""oropharynx"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""hypopharynx"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""larynx"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""incurable"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""local therapies"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""treatment naïve"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""PD-1/PD-L1 targeting agent"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""recurrent HNSCC""
    },
    {
        ""id"": 2,
        ""type"": ""Procedure/Device"",
        ""name"": ""curative treatment""
    },
    {
        ""id"": 3,
        ""type"": ""Procedure/Device"",
        ""name"": ""local therapy""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""systemic therapy""
    },
    {
        ""id"": 5,
        ""type"": ""Condition"",
        ""name"": ""metastatic HNSCC""
    },
    {
        ""id"": 6,
        ""type"": ""Observation"",
        ""name"": ""oral cavity""
    },
    {
        ""id"": 7,
        ""type"": ""Observation"",
        ""name"": ""oropharynx""
    },
    {
        ""id"": 8,
        ""type"": ""Observation"",
        ""name"": ""hypopharynx""
    },
    {
        ""id"": 9,
        ""type"": ""Observation"",
        ""name"": ""larynx""
    },
    {
        ""id"": 10,
        ""type"": ""Procedure/Device"",
        ""name"": ""local therapies""
    },
    {
        ""id"": 11,
        ""type"": ""Drug/Substance"",
        ""name"": ""PD-1/PD-L1 targeting agent""
    }
]
```"
NCT03071757,Inclusion: Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2.,"```json
[
    {
        ""entity"": ""Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""0 to 2"",
        ""category"": ""Measurement""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 0,
                ""upper_bound"": 2,
                ""unit"": """"
            }
        }
    }
]
```"
NCT03071757,Inclusion: Participants must have immune-related Response Evaluation Criteria for Solid Tumors (iRECIST) evaluable or measurable disease in the PART 1 and measurable disease per iRECIST in PART 2,"```json
[
    {
        ""entity"": ""immune-related Response Evaluation Criteria for Solid Tumors (iRECIST)"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""evaluable or measurable disease"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""PART 1"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""measurable disease"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""iRECIST"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""PART 2"",
        ""category"": ""Temporal Constraints""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""immune-related Response Evaluation Criteria for Solid Tumors (iRECIST)""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""evaluable or measurable disease""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""measurable disease""
    },
    {
        ""id"": 4,
        ""type"": ""Observation"",
        ""name"": ""iRECIST""
    }
]
```"
NCT03071757,"Inclusion: Adequate bone marrow, kidney and liver function.","```json
[
    {
        ""entity"": ""Adequate bone marrow function"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""Adequate kidney function"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""Adequate liver function"",
        ""category"": ""Observation""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Adequate bone marrow function""
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""Adequate kidney function""
    },
    {
        ""id"": 3,
        ""type"": ""Observation"",
        ""name"": ""Adequate liver function""
    }
]
```"
NCT03071757,"Exclusion: Received anticancer therapy including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or any investigational therapy within a period of 21 days prior to the first dose of ABBV-368.","```json
[
    {
        ""entity"": ""anticancer therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""chemotherapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""immunotherapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""radiation therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""biologic"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""herbal therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""investigational therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""within a period of 21 days"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""prior to the first dose of ABBV-368"",
        ""category"": ""Temporal Constraints""
    }
]
```","```python
def extract_events(inputs: Dict[str, Any]) -> str:
    """"""
    This is function is used to identify and extract structured events and attributes related to the specified entities from the input text.
    The entities, along with their types and names, have been identified in a previous step and are provided for reference.

    The function takes a dictionary of `inputs` as an argument, which contains the following keys:
    - 'input_text': the input eligibility criteria in text format
    - 'entities': a list of entities, each containing the type and name of an entity identified in the input text
        e.g., [""Condition: Type 2 diabetes mellitus"", ""Drug/Substance: Metformin"", ""Measurement: Serum creatinine"", ""Procedure/Device: Chemotherapy"", ""Observation: Smoking"", ""Observation: 30 to 75 years old"", ...]

    The function should return a list of dictionaries, each containing the extracted events and attributes for the specified entities.
    - Event entity types include: `Condition`, `Observation`, `Procedure/Device`, `Drug/Substance`.
    - Attribute entities include: `Measurement`, `Temporal Constraints`, `Qualifiers/Modifiers`.

    The formats of the target extracted events are as follows:


    Observation:
    {
        ""id"": int, \\ the unique identifier of the event, starting from 1 to N
        ""type"":""Observation"",
        ""name"": str, \\ the name of the observation
        ""occurrence"": {
            ""operator"": str, \\ the operator of the occurrence, in [""at least"", ""at most"", ""exactly""]
            ""number"": int, \\ the number of occurrence
        },
        ""temporal"": {
            ""start"": {
                ""number"": int, \\ the number of days/months/years/etc before the reference event
                ""unit"": str, \\ the unit of the temporal, in [""days"", ""weeks"", ""months"", ""years""]
            },
            ""end"":{
                ""number"": int, \\ the number of days/months/years/etc after the reference event
                ""unit"": str, \\ the unit of the temporal, in [""days"", ""weeks"", ""months"", ""years""]
            },
            ""reference_event"": int, \\ the reference event id for the start and end window
        },
        ""value"":{
            ""range"": {
                ""lower_bound"": float, \\ the lower bound of the measurement value
                ""upper_bound"": float, \\ the upper bound of the measurement value
                ""unit"": str, \\ the unit of the measurement value
            },
            ""qualitative"": str, \\  the qualitative value of the measurement, e.g., ""positive"", ""negative"", ""normal"", ""abnormal"", etc.
        },
    }

    Condition:
    {
        ""id"": int, \\ the unique identifier of the event, starting from 1 to N
        ""type"":""Condition"", \\ the type of the entity
        ""name"": str, \\ the name of the condition
        ""occurrence"": {
            ""operator"": str, \\ the operator of the occurrence, in [""at least"", ""at most"", ""exactly""]
            ""number"": int, \\ the number of occurrences 
            }},
        ""temporal"": {
            ""start"": {
                ""number"": int, \\ the number of days/months/years/etc before the reference event
                ""unit"": str, \\ the unit of the temporal, in [""days"", ""weeks"", ""months"", ""years""]
            }},
            ""end"":{
                ""number"": int, \\ the number of days/months/years/etc after the reference event
                ""unit"": str, \\ the unit of the temporal, in [""days"", ""weeks"", ""months"", ""years""]
            }},
            ""reference_event"": int, \\ the reference event id for the start and end window
        }
    }

    Drug/Substance:
    {
        ""id"": int, \\ the unique identifier of the event, starting from 1 to N
        ""type"":""Drug/Substance"",
        ""name"": str, \\ the name of the drug
        ""occurrence"": {
            ""operator"": str, \\ the operator of the occurrence, in [""at least"", ""at most"", ""exactly""]
            ""number"": int, \\ the number of occurrence
        },
        ""temporal"": {
            ""start"": {
                ""number"": int, \\ the number of days/months/years/etc before the reference event
                ""unit"": str, \\ the unit of the temporal, in [""days"", ""weeks"", ""months"", ""years""]
            },
            ""end"":{
                ""number"": int, \\ the number of days/months/years/etc after the reference event
                ""unit"": str, \\ the unit of the temporal, in [""days"", ""weeks"", ""months"", ""years""]
            }},
            ""reference_event"": int, \\ the reference event id for the start and end window
        }
    }

    Procedure/Device:
    {
        ""id"": int, \\ the unique identifier of the event, starting from 1 to N
        ""type"":""Procedure/Device"",
        ""name"": str, \\ the name of the procedure
        ""occurrence"": {
            ""operator"": str, \\ the operator of the occurrence, in [""at least"", ""at most"", ""exactly""]
            ""number"": int, \\ the number of occurrence
        },
        ""temporal"": {
            ""start"": {
                ""number"": int, \\ the number of days/months/years/etc before the reference event
                ""unit"": str, \\ the unit of the temporal, in [""days"", ""weeks"", ""months"", ""years""]
            },
            ""end"":{
                ""number"": int, \\ the number of days/months/years/etc after the reference event
                ""unit"": str, \\ the unit of the temporal, in [""days"", ""weeks"", ""months"", ""years""]
            }},
            ""reference_event"": int, \\ the reference event id for the start and end window
        }
    }

    IMPORTANT: 
    - for all the events, the fields 'id', 'type', 'name' are mandatory, the other fields are optional and should be included only if they are present in the input text.
    - for all the events, the field 'type' must be one of the following: 'Condition', 'Observation', 'Procedure/Device', 'Drug/Substance'.

    The function should return a syntactically correct JSON format string that contains a list of the extracted events, each event should be one of the above formats.
    The output is wrapped within  ```json and ``` tags, for example:
    ```json
    [
        {
            ""id"": 1, \\ the unique identifier of the event, starting from 1 to N
            ""type"":""Observation"", \\ the type of the entity
            ""name"": ""age"", \\ the name of the observation
            ""value"":{
                ""range"": {
                    ""lower_bound"": float, \\ the lower bound of the age value
                    ""upper_bound"": float, \\ the upper bound of the age value
                    ""unit"": str, \\ the unit of the age value
                }},
        },
        ... \\ other events
    ]
    ```

    Returns:
    - str: a JSON format string that contains a list of the extracted events, wrapped by ```json and ``` tags
    """"""
```

# Provided inputs
input_text = """"""Patients must not have received any anticancer therapy including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or investigational therapy within a period of 21 days prior to the first dose of ABBV-368.""""""
entities = """"""[
    {
        ""entity"": ""anticancer therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""chemotherapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""immunotherapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""radiation therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""biologic"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""herbal therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""investigational therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""within a period of 21 days"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""prior to the first dose of ABBV-368"",
        ""category"": ""Temporal Constraints""
    }
]""""""

inputs = {
    ""input_text"": input_text,
    ""entities"": entities
}

# Function implementation
def extract_events(inputs: Dict[str, Any]) -> str:
    import json

    input_text = inputs[""input_text""]
    entities = json.loads(inputs[""entities""])

    events = []
    event_id = 1

    for entity in entities:
        if entity[""category""] == ""Drug/Substance"":
            event = {
                ""id"": event_id,
                ""type"": ""Drug/Substance"",
                ""name"": entity[""entity""]
            }
            event_id += 1
            events.append(event)

    # Adding temporal constraints to the last event
    for event in events:
        event[""temporal""] = {
            ""start"": {
                ""number"": 21,
                ""unit"": ""days""
            },
            ""reference_event"": ""first dose of ABBV-368""
        }

    return json.dumps(events, indent=4)

# Output
print(extract_events(inputs))
```json
[
    {
        ""id"": 1,
        ""type"": ""Drug/Substance"",
        ""name"": ""anticancer therapy"",
        ""temporal"": {
            ""start"": {
                ""number"": 21,
                ""unit"": ""days""
            },
            ""reference_event"": ""first dose of ABBV-368""
        }
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""chemotherapy"",
        ""temporal"": {
            ""start"": {
                ""number"": 21,
                ""unit"": ""days""
            },
            ""reference_event"": ""first dose of ABBV-368""
        }
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""immunotherapy"",
        ""temporal"": {
            ""start"": {
                ""number"": 21,
                ""unit"": ""days""
            },
            ""reference_event"": ""first dose of ABBV-368""
        }
    },
    {
        ""id"": 4,
        ""type"": ""Drug/Substance"",
        ""name"": ""radiation therapy"",
        ""temporal"": {
            ""start"": {
                ""number"": 21,
                ""unit"": ""days""
            },
            ""reference_event"": ""first dose of ABBV-368""
        }
    },
    {
        ""id"": 5,
        ""type"": ""Drug/Substance"",
        ""name"": ""biologic"",
        ""temporal"": {
            ""start"": {
                ""number"": 21,
                ""unit"": ""days""
            },
            ""reference_event"": ""first dose of ABBV-368""
        }
    },
    {
        ""id"": 6,
        ""type"": ""Drug/Substance"",
        ""name"": ""herbal therapy"",
        ""temporal"": {
            ""start"": {
                ""number"": 21,
                ""unit"": ""days""
            },
            ""reference_event"": ""first dose of ABBV-368""
        }
    },
    {
        ""id"": 7,
        ""type"": ""Drug/Substance"",
        ""name"": ""investigational therapy"",
        ""temporal"": {
            ""start"": {
                ""number"": 21,
                ""unit"": ""days""
            },
            ""reference_event"": ""first dose of ABBV-368""
        }
    }
]
```"
NCT03071757,Exclusion: Prior treatment with an OX40 targeting agent.,"```json
[
    {
        ""entity"": ""Prior"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""treatment"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""OX40 targeting agent"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Procedure/Device"",
        ""name"": ""treatment""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""OX40 targeting agent"",
        ""temporal"": {
            ""start"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""end"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""reference_event"": 1
        }
    }
]
```"
NCT03071757,Exclusion: has known uncontrolled metastases to the central nervous system (CNS).,"```json
[
    {
        ""entity"": ""uncontrolled metastases"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""central nervous system (CNS)"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""uncontrolled metastases""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""central nervous system (CNS)""
    }
]
```"
NCT03071757,Exclusion: History of active autoimmune disorders and other conditions that compromise or impair the immune system.,"```json
[
    {
        ""entity"": ""History of active autoimmune disorders"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""other conditions that compromise or impair the immune system"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""History of active autoimmune disorders""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""other conditions that compromise or impair the immune system""
    }
]
```"
NCT03071757,"Exclusion: Confirmed positive test results for human immunodeficiency virus (HIV), or subjects with chronic or active hepatitis A, B or C. Subjects who have a history of hepatitis B or C who have documented cures after anti-viral therapy may be enrolled.","```json
[
    {
        ""entity"": ""Confirmed positive test results"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""human immunodeficiency virus (HIV)"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""chronic or active hepatitis A, B or C"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""history of hepatitis B or C"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""documented cures after anti-viral therapy"",
        ""category"": ""Qualifiers/Modifiers""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""human immunodeficiency virus (HIV)""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""chronic or active hepatitis A, B or C""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""history of hepatitis B or C""
    }
]
```"
NCT03071757,Exclusion: Has received live vaccine within 28 days prior to the first dose of study drug.,"```json
[
    {
        ""entity"": ""live vaccine"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""within 28 days"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""prior to the first dose of study drug"",
        ""category"": ""Temporal Constraints""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Drug/Substance"",
        ""name"": ""live vaccine"",
        ""temporal"": {
            ""start"": {
                ""number"": 28,
                ""unit"": ""days""
            },
            ""reference_event"": ""prior to the first dose of study drug""
        }
    }
]
```"
NCT04495257,Inclusion: 1. At least 1 site of disease must be accessible to provide repeat biopsies for tumor tissue. The biopsy may be waived if not feasible upon discussion with the study PIs. This site may be a target lesion as long as it will not be rendered unmeasurable by the biopsy procedure.,"```json
[
    {
        ""entity"": ""disease"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""biopsies"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""tumor tissue"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""biopsy"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""target lesion"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""biopsy procedure"",
        ""category"": ""Procedure/Device""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""disease""
    },
    {
        ""id"": 2,
        ""type"": ""Procedure/Device"",
        ""name"": ""biopsies""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""tumor tissue""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""biopsy""
    },
    {
        ""id"": 5,
        ""type"": ""Condition"",
        ""name"": ""target lesion""
    },
    {
        ""id"": 6,
        ""type"": ""Procedure/Device"",
        ""name"": ""biopsy procedure""
    }
]
```"
NCT04495257,Exclusion: 1. Untreated brain metastases. 2. A patient who has had prior treatment with immune therapy for advanced disease. Prior immune checkpoint inhibitors as adjuvant therapy is allowed provided at least 6 months have lapsed from the last dose. Prior targeted therapy is allowed as long as 2 weeks have passed.,"```json
[
    {
        ""entity"": ""Untreated brain metastases"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""prior treatment with immune therapy for advanced disease"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""Prior immune checkpoint inhibitors as adjuvant therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""at least 6 months"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""Prior targeted therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""2 weeks"",
        ""category"": ""Temporal Constraints""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Untreated brain metastases""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""prior treatment with immune therapy for advanced disease""
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""Prior immune checkpoint inhibitors as adjuvant therapy"",
        ""temporal"": {
            ""start"": {
                ""number"": 6,
                ""unit"": ""months""
            }
        }
    },
    {
        ""id"": 4,
        ""type"": ""Drug/Substance"",
        ""name"": ""Prior targeted therapy"",
        ""temporal"": {
            ""start"": {
                ""number"": 2,
                ""unit"": ""weeks""
            }
        }
    }
]
```"
NCT02771626,"Inclusion: Ability to provide written informed consent in accordance with federal, local, and institutional guidelines","```json
[]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Type 2 diabetes mellitus""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""Metformin""
    },
    {
        ""id"": 3,
        ""type"": ""Measurement"",
        ""name"": ""Serum creatinine""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""Chemotherapy""
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""Smoking""
    },
    {
        ""id"": 6,
        ""type"": ""Observation"",
        ""name"": ""30 to 75 years old"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 30,
                ""upper_bound"": 75,
                ""unit"": ""years""
            }
        }
    }
]
```"
NCT02771626,Inclusion: Histological or cytological diagnosis of metastatic cancer or locally advanced cancer that is not amenable to local therapy,"```json
[
    {
        ""entity"": ""Histological or cytological diagnosis"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""metastatic cancer"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""locally advanced cancer"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""not amenable to local therapy"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Histological or cytological diagnosis""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""metastatic cancer""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""locally advanced cancer""
    },
    {
        ""id"": 4,
        ""type"": ""Condition"",
        ""name"": ""not amenable to local therapy""
    }
]
```"
NCT02771626,Inclusion: Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1,"```json
[
    {
        ""entity"": ""Eastern Cooperative Oncology Group (ECOG) Performance Status"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""0-1"",
        ""category"": ""Measurement""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Eastern Cooperative Oncology Group (ECOG) Performance Status"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 0,
                ""upper_bound"": 1,
                ""unit"": """"
            }
        }
    }
]
```"
NCT02771626,Inclusion: Life Expectancy of at least 3 months,"```json
[
    {
        ""entity"": ""Life Expectancy"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""at least 3 months"",
        ""category"": ""Measurement""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Life Expectancy"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 3,
                ""unit"": ""months""
            }
        }
    }
]
```"
NCT02771626,"Inclusion: Adequate hepatic, renal, cardiac, and hematologic function","```json
[
    {
        ""entity"": ""Adequate hepatic function"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""Adequate renal function"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""Adequate cardiac function"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""Adequate hematologic function"",
        ""category"": ""Observation""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Adequate hepatic function""
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""Adequate renal function""
    },
    {
        ""id"": 3,
        ""type"": ""Observation"",
        ""name"": ""Adequate cardiac function""
    },
    {
        ""id"": 4,
        ""type"": ""Observation"",
        ""name"": ""Adequate hematologic function""
    }
]
```"
NCT02771626,Inclusion: Measurable disease by Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria,"```json
[
    {
        ""entity"": ""Measurable disease"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria"",
        ""category"": ""Observation""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Measurable disease""
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria""
    }
]
```"
NCT02771626,Inclusion: Resolution of treatment-related toxicities except alopecia,"```json
[
    {
        ""entity"": ""treatment-related toxicities"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""alopecia"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""treatment-related toxicities""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""alopecia""
    }
]
```"
NCT02771626,Exclusion: Unable to receive oral medications,"```json
[
    {
        ""entity"": ""Unable"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""oral medications"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Unable""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""oral medications""
    }
]
```"
NCT02771626,Exclusion: Unable to receive oral or intravenous (IV) hydration,"```json
[
    {
        ""entity"": ""Unable"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""oral hydration"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""intravenous (IV) hydration"",
        ""category"": ""Procedure/Device""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Unable""
    },
    {
        ""id"": 2,
        ""type"": ""Procedure/Device"",
        ""name"": ""oral hydration""
    },
    {
        ""id"": 3,
        ""type"": ""Procedure/Device"",
        ""name"": ""intravenous (IV) hydration""
    }
]
```"
NCT02771626,Exclusion: Intolerance to prior anti-PD-1/PD-L1 therapy,"```json
[
    {
        ""entity"": ""Intolerance"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""prior anti-PD-1/PD-L1 therapy"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Intolerance""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""prior anti-PD-1/PD-L1 therapy""
    }
]
```"
NCT02771626,Exclusion: Prior severe hypersensitivity reaction to another monoclonal antibody (mAb),"```json
[
    {
        ""entity"": ""Prior"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""severe"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""hypersensitivity reaction"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""monoclonal antibody (mAb)"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""hypersensitivity reaction"",
        ""occurrence"": {
            ""operator"": ""at least"",
            ""number"": 1
        },
        ""temporal"": {
            ""start"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""end"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""reference_event"": 0
        }
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""monoclonal antibody (mAb)"",
        ""occurrence"": {
            ""operator"": ""at least"",
            ""number"": 1
        },
        ""temporal"": {
            ""start"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""end"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""reference_event"": 0
        }
    }
]
```"
NCT02771626,Exclusion: Any other current or previous malignancy within 3 years except protocol allowed malignancies,"```json
[
    {
        ""entity"": ""current or previous malignancy"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""within 3 years"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""protocol allowed malignancies"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""current or previous malignancy"",
        ""temporal"": {
            ""start"": {
                ""number"": 3,
                ""unit"": ""years""
            },
            ""end"": {
                ""number"": 0,
                ""unit"": ""years""
            },
            ""reference_event"": 1
        }
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""protocol allowed malignancies""
    }
]
```"
NCT02771626,"Exclusion: Chemotherapy, TKI therapy, radiation therapy or hormonal therapy within 2 weeks","```json
[
    {
        ""entity"": ""Chemotherapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""TKI therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""radiation therapy"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""hormonal therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""within 2 weeks"",
        ""category"": ""Temporal Constraints""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Drug/Substance"",
        ""name"": ""Chemotherapy""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""TKI therapy""
    },
    {
        ""id"": 3,
        ""type"": ""Procedure/Device"",
        ""name"": ""radiation therapy""
    },
    {
        ""id"": 4,
        ""type"": ""Drug/Substance"",
        ""name"": ""hormonal therapy""
    }
]
```"
NCT02771626,"Exclusion: Immunotherapy or biological therapy, or investigational agent within 3 weeks (Note: Some cohort exceptions allow anti-PD-1 therapy)","```json
[
    {
        ""entity"": ""Immunotherapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""biological therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""investigational agent"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""within 3 weeks"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""anti-PD-1 therapy"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Drug/Substance"",
        ""name"": ""Immunotherapy""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""biological therapy""
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""investigational agent""
    },
    {
        ""id"": 4,
        ""type"": ""Drug/Substance"",
        ""name"": ""anti-PD-1 therapy"",
        ""temporal"": {
            ""start"": {
                ""number"": 3,
                ""unit"": ""weeks""
            }
        }
    }
]
```"
NCT02771626,Exclusion: Active known or suspected exclusionary autoimmune disease,"```json
[
    {
        ""entity"": ""Active"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""known or suspected exclusionary autoimmune disease"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""known or suspected exclusionary autoimmune disease""
    }
]
```"
NCT02771626,Exclusion: Any condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalent) or other systemic immunosuppressive medications within 2 weeks,"```json
[
    {
        ""entity"": ""condition"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""systemic treatment"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""corticosteroids"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""> 10 mg daily prednisone equivalent"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""systemic immunosuppressive medications"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""within 2 weeks"",
        ""category"": ""Temporal Constraints""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""condition""
    },
    {
        ""id"": 2,
        ""type"": ""Procedure/Device"",
        ""name"": ""systemic treatment""
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""corticosteroids"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 10,
                ""unit"": ""mg daily prednisone equivalent""
            }
        }
    },
    {
        ""id"": 4,
        ""type"": ""Drug/Substance"",
        ""name"": ""systemic immunosuppressive medications"",
        ""temporal"": {
            ""start"": {
                ""number"": 2,
                ""unit"": ""weeks""
            },
            ""reference_event"": 2
        }
    }
]
```"
NCT02771626,Exclusion: History of known risks factors for bowel perforation,"```json
[
    {
        ""entity"": ""History of known risks factors for bowel perforation"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""History of known risks factors for bowel perforation""
    }
]
```"
NCT02771626,Exclusion: Symptomatic ascites or pleural effusion,"```json
[
    {
        ""entity"": ""Symptomatic ascites"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""pleural effusion"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Symptomatic ascites""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""pleural effusion""
    }
]
```"
NCT02771626,Exclusion: Major surgery within 28 days before Cycle 1 Day 1,"```json
[
    {
        ""entity"": ""Major surgery"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""within 28 days before Cycle 1 Day 1"",
        ""category"": ""Temporal Constraints""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Procedure/Device"",
        ""name"": ""Major surgery"",
        ""temporal"": {
            ""start"": {
                ""number"": 28,
                ""unit"": ""days""
            },
            ""reference_event"": 1
        }
    }
]
```"
NCT02771626,"Exclusion: Active infection requiring parenteral antibiotics, antivirals, or antifungals within 2 weeks prior to first dose of study drug","```json
[
    {
        ""entity"": ""Active infection"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""parenteral antibiotics"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""antivirals"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""antifungals"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""within 2 weeks"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""prior to first dose of study drug"",
        ""category"": ""Temporal Constraints""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Active infection"",
        ""temporal"": {
            ""start"": {
                ""number"": 2,
                ""unit"": ""weeks""
            },
            ""reference_event"": 2
        }
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""parenteral antibiotics"",
        ""temporal"": {
            ""start"": {
                ""number"": 2,
                ""unit"": ""weeks""
            },
            ""reference_event"": 3
        }
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""antivirals"",
        ""temporal"": {
            ""start"": {
                ""number"": 2,
                ""unit"": ""weeks""
            },
            ""reference_event"": 3
        }
    },
    {
        ""id"": 4,
        ""type"": ""Drug/Substance"",
        ""name"": ""antifungals"",
        ""temporal"": {
            ""start"": {
                ""number"": 2,
                ""unit"": ""weeks""
            },
            ""reference_event"": 3
        }
    }
]
```"
NCT02771626,"Exclusion: Patients who have human immunodeficiency virus (HIV), Hepatitis B or C","```json
[
    {
        ""entity"": ""human immunodeficiency virus (HIV)"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""Hepatitis B"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""Hepatitis C"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""human immunodeficiency virus (HIV)""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""Hepatitis B""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""Hepatitis C""
    }
]
```"
NCT02771626,Exclusion: Conditions that could interfere with treatment or protocol-related procedures,"```json
[
    {
        ""entity"": ""Conditions"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""treatment"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""protocol-related procedures"",
        ""category"": ""Procedure/Device""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Conditions""
    },
    {
        ""id"": 2,
        ""type"": ""Procedure/Device"",
        ""name"": ""treatment""
    },
    {
        ""id"": 3,
        ""type"": ""Procedure/Device"",
        ""name"": ""protocol-related procedures""
    }
]
```"
NCT02771626,Exclusion: Active and/or untreated central nervous system (CNS) disease or non-stable brain metastases,"```json
[
    {
        ""entity"": ""Active"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""untreated"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""central nervous system (CNS) disease"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""non-stable"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""brain metastases"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""central nervous system (CNS) disease""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""brain metastases""
    }
]
```"
NCT05267626,"Inclusion: Measurable or non-measurable disease as per RECIST v1.1 criteria and documented by CT and/or MRI. In Cohort Expansion, patients with truly non-measurable only disease (e.g., ascites, pleural or pericardial effusion, organomegaly), are not eligible for enrollment","```json
[
    {
        ""entity"": ""Measurable or non-measurable disease"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""RECIST v1.1 criteria"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""CT"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""MRI"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""Cohort Expansion"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""truly non-measurable only disease"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""ascites"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""pleural effusion"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""pericardial effusion"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""organomegaly"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Measurable or non-measurable disease""
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""RECIST v1.1 criteria""
    },
    {
        ""id"": 3,
        ""type"": ""Procedure/Device"",
        ""name"": ""CT""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""MRI""
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""Cohort Expansion""
    },
    {
        ""id"": 6,
        ""type"": ""Condition"",
        ""name"": ""truly non-measurable only disease""
    },
    {
        ""id"": 7,
        ""type"": ""Condition"",
        ""name"": ""ascites""
    },
    {
        ""id"": 8,
        ""type"": ""Condition"",
        ""name"": ""pleural effusion""
    },
    {
        ""id"": 9,
        ""type"": ""Condition"",
        ""name"": ""pericardial effusion""
    },
    {
        ""id"": 10,
        ""type"": ""Condition"",
        ""name"": ""organomegaly""
    }
]
```"
NCT05267626,"Inclusion: In Dose Escalation patients must have selected tumor types and have progressed after standard of care treatment, or be intolerant to treatment, or refused standard treatment","```json
[
    {
        ""entity"": ""selected tumor types"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""progressed"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""standard of care treatment"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""intolerant"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""treatment"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""refused"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""standard treatment"",
        ""category"": ""Procedure/Device""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""selected tumor types""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""progressed""
    },
    {
        ""id"": 3,
        ""type"": ""Procedure/Device"",
        ""name"": ""standard of care treatment""
    },
    {
        ""id"": 4,
        ""type"": ""Observation"",
        ""name"": ""intolerant""
    },
    {
        ""id"": 5,
        ""type"": ""Procedure/Device"",
        ""name"": ""treatment""
    },
    {
        ""id"": 6,
        ""type"": ""Observation"",
        ""name"": ""refused""
    },
    {
        ""id"": 7,
        ""type"": ""Procedure/Device"",
        ""name"": ""standard treatment""
    }
]
```"
NCT05267626,Inclusion: Part 2 includes but is not limited to:,"```json
[]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Type 2 diabetes mellitus""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""Metformin""
    },
    {
        ""id"": 3,
        ""type"": ""Measurement"",
        ""name"": ""Serum creatinine""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""Chemotherapy""
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""Smoking""
    },
    {
        ""id"": 6,
        ""type"": ""Observation"",
        ""name"": ""30 to 75 years old"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 30,
                ""upper_bound"": 75,
                ""unit"": ""years""
            }
        }
    }
]
```"
NCT05267626,"Inclusion: Renal cell cancer progressing during or following at least two approved therapeutic regimens (e.g., small molecule inhibitors, anti-PDx therapy)","```json
[
    {
        ""entity"": ""Renal cell cancer"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""progressing"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""at least two approved therapeutic regimens"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""small molecule inhibitors"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""anti-PDx therapy"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Renal cell cancer""
    },
    {
        ""id"": 2,
        ""type"": ""Procedure/Device"",
        ""name"": ""at least two approved therapeutic regimens"",
        ""occurrence"": {
            ""operator"": ""at least"",
            ""number"": 2
        }
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""small molecule inhibitors""
    },
    {
        ""id"": 4,
        ""type"": ""Drug/Substance"",
        ""name"": ""anti-PDx therapy""
    }
]
```"
NCT05267626,Inclusion: Cutaneous melanoma that is either locally unresectable or metastatic:,"```json
[
    {
        ""entity"": ""Cutaneous melanoma"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""locally unresectable"",
        ""category"": ""Qualifier/Modifier""
    },
    {
        ""entity"": ""metastatic"",
        ""category"": ""Qualifier/Modifier""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Cutaneous melanoma""
    }
]
```"
NCT05267626,Inclusion: NSCLC: Unresectable locally advanced or metastatic PD-L1-positive (≥ 1%) NSCLC not harboring an activating EGFR mutation or ALK rearrangement and has progressed during or following treatment with an anti-PDx and platinum-based chemotherapy (unless ineligible for platinum therapy),"```json
[
    {
        ""entity"": ""NSCLC"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""Unresectable locally advanced or metastatic"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""PD-L1-positive (≥ 1%)"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""NSCLC"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""activating EGFR mutation"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""ALK rearrangement"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""progressed during or following treatment"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""anti-PDx"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""platinum-based chemotherapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""ineligible for platinum therapy"",
        ""category"": ""Qualifiers/Modifiers""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""NSCLC""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""NSCLC"",
        ""qualifiers"": [
            ""Unresectable locally advanced or metastatic"",
            ""PD-L1-positive (≥ 1%)""
        ]
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""activating EGFR mutation""
    },
    {
        ""id"": 4,
        ""type"": ""Condition"",
        ""name"": ""ALK rearrangement""
    },
    {
        ""id"": 5,
        ""type"": ""Condition"",
        ""name"": ""NSCLC"",
        ""qualifiers"": [
            ""progressed during or following treatment""
        ]
    },
    {
        ""id"": 6,
        ""type"": ""Drug/Substance"",
        ""name"": ""anti-PDx""
    },
    {
        ""id"": 7,
        ""type"": ""Drug/Substance"",
        ""name"": ""platinum-based chemotherapy""
    },
    {
        ""id"": 8,
        ""type"": ""Condition"",
        ""name"": ""NSCLC"",
        ""qualifiers"": [
            ""ineligible for platinum therapy""
        ]
    }
]
```"
NCT05267626,Inclusion: Part 3: NSCLC as described above,"```json
[
    {
        ""entity"": ""NSCLC"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""NSCLC""
    }
]
```"
NCT05267626,"Inclusion: Female patients of childbearing potential must have a negative serum or urine pregnancy test performed within 72 hours prior to the initiation of study drug administration. Female patients of childbearing potential must be willing to use two forms of contraception throughout the study, starting with Screening through 60 days after the last dose of study drug. Abstinence is acceptable if this is the established and the preferred contraception method for the patient","```json
[
    {
        ""entity"": ""Female patients of childbearing potential"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""negative"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""serum or urine pregnancy test"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""within 72 hours"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""prior to the initiation of study drug administration"",
        ""category"": ""Temporal Constraints""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Female patients of childbearing potential""
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""serum or urine pregnancy test"",
        ""value"": {
            ""qualitative"": ""negative""
        },
        ""temporal"": {
            ""start"": {
                ""number"": 72,
                ""unit"": ""hours""
            },
            ""reference_event"": 3
        }
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""initiation of study drug administration""
    }
]
```"
NCT05267626,"Inclusion: Male patients with partners of childbearing potential must use barrier contraception from the time of consent through 60 days after discontinuation of study drug and must not donate sperm during this period. In addition, male patients should have their partners use contraception (as documented for female patients) for the same period of time","```json
[]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Type 2 diabetes mellitus""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""Metformin""
    },
    {
        ""id"": 3,
        ""type"": ""Measurement"",
        ""name"": ""Serum creatinine""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""Chemotherapy""
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""Smoking""
    },
    {
        ""id"": 6,
        ""type"": ""Observation"",
        ""name"": ""30 to 75 years old"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 30,
                ""upper_bound"": 75,
                ""unit"": ""years""
            }
        }
    }
]
```"
NCT05267626,"Inclusion: Patients who have previously received an immune checkpoint inhibitor (e.g., anti-PD-L1, anti-PD-1, anti-CTLA-4) prior to enrollment must have checkpoint inhibitor immune-related toxicity resolved to either Grade ≤ 1 or baseline (prior to the checkpoint inhibitor) to be eligible for enrollment. Patients who experienced previous checkpoint inhibitor-related hypothyroidism are eligible for the study regardless of grade resolution if well controlled on thyroid hormone replacement therapy","```json
[
    {
        ""entity"": ""immune checkpoint inhibitor"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""anti-PD-L1"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""anti-PD-1"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""anti-CTLA-4"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""prior to enrollment"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""checkpoint inhibitor immune-related toxicity"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""Grade ≤ 1"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""baseline"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""previous checkpoint inhibitor-related hypothyroidism"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""well controlled"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""thyroid hormone replacement therapy"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Drug/Substance"",
        ""name"": ""immune checkpoint inhibitor""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""anti-PD-L1""
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""anti-PD-1""
    },
    {
        ""id"": 4,
        ""type"": ""Drug/Substance"",
        ""name"": ""anti-CTLA-4""
    },
    {
        ""id"": 5,
        ""type"": ""Condition"",
        ""name"": ""checkpoint inhibitor immune-related toxicity""
    },
    {
        ""id"": 6,
        ""type"": ""Condition"",
        ""name"": ""previous checkpoint inhibitor-related hypothyroidism""
    },
    {
        ""id"": 7,
        ""type"": ""Drug/Substance"",
        ""name"": ""thyroid hormone replacement therapy""
    }
]
```"
NCT05267626,"Inclusion: Symptomatic central nervous system (CNS) metastases must have been treated, be asymptomatic for ≥ 14 days, and meet the following at the time of enrollment:","```json
[
    {
        ""entity"": ""Symptomatic central nervous system (CNS) metastases"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""treated"",
        ""category"": ""Qualifier/Modifier""
    },
    {
        ""entity"": ""asymptomatic"",
        ""category"": ""Qualifier/Modifier""
    },
    {
        ""entity"": ""≥ 14 days"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""at the time of enrollment"",
        ""category"": ""Temporal Constraints""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Symptomatic central nervous system (CNS) metastases"",
        ""occurrence"": {
            ""operator"": ""at least"",
            ""number"": 1
        },
        ""temporal"": {
            ""start"": {
                ""number"": 14,
                ""unit"": ""days""
            },
            ""end"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""reference_event"": 1
        }
    }
]
```"
NCT05267626,Exclusion: Patients with a history of known autoimmune disease with exceptions of,"```json
[
    {
        ""entity"": ""history"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""known autoimmune disease"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""history""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""known autoimmune disease""
    }
]
```"
NCT05267626,Exclusion: Major surgery or traumatic injury within 8 weeks before first dose of AU-007,"```json
[
    {
        ""entity"": ""Major surgery"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""traumatic injury"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""within 8 weeks"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""before first dose of AU-007"",
        ""category"": ""Temporal Constraints""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Procedure/Device"",
        ""name"": ""Major surgery"",
        ""temporal"": {
            ""start"": {
                ""number"": 8,
                ""unit"": ""weeks""
            },
            ""reference_event"": ""first dose of AU-007""
        }
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""traumatic injury"",
        ""temporal"": {
            ""start"": {
                ""number"": 8,
                ""unit"": ""weeks""
            },
            ""reference_event"": ""first dose of AU-007""
        }
    }
]
```"
NCT05267626,Exclusion: Unhealed wounds from surgery or injury,"```json
[
    {
        ""entity"": ""Unhealed wounds"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""surgery"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""injury"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Unhealed wounds""
    },
    {
        ""id"": 2,
        ""type"": ""Procedure/Device"",
        ""name"": ""surgery""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""injury""
    }
]
```"
NCT05267626,"Exclusion: Treatment with \> 10 mg per day of prednisone (or equivalent) or other immune-suppressive drugs within the 7 days prior to the initiation of study drug. Steroids for topical, ophthalmic, inhaled, or nasal administration are allowed","```json
[
    {
        ""entity"": ""Treatment"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""> 10 mg per day"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""prednisone (or equivalent)"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""immune-suppressive drugs"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""within the 7 days prior to the initiation of study drug"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""Steroids"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""topical, ophthalmic, inhaled, or nasal administration"",
        ""category"": ""Procedure/Device""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Procedure/Device"",
        ""name"": ""Treatment""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""prednisone (or equivalent)"",
        ""occurrence"": {
            ""operator"": ""at least"",
            ""number"": 1
        },
        ""temporal"": {
            ""start"": {
                ""number"": 7,
                ""unit"": ""days""
            },
            ""reference_event"": 1
        },
        ""value"": {
            ""range"": {
                ""lower_bound"": 10,
                ""unit"": ""mg per day""
            }
        }
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""immune-suppressive drugs"",
        ""occurrence"": {
            ""operator"": ""at least"",
            ""number"": 1
        },
        ""temporal"": {
            ""start"": {
                ""number"": 7,
                ""unit"": ""days""
            },
            ""reference_event"": 1
        }
    },
    {
        ""id"": 4,
        ""type"": ""Drug/Substance"",
        ""name"": ""Steroids"",
        ""occurrence"": {
            ""operator"": ""at least"",
            ""number"": 1
        },
        ""temporal"": {
            ""start"": {
                ""number"": 7,
                ""unit"": ""days""
            },
            ""reference_event"": 1
        }
    },
    {
        ""id"": 5,
        ""type"": ""Procedure/Device"",
        ""name"": ""topical, ophthalmic, inhaled, or nasal administration""
    }
]
```"
NCT05267626,Exclusion: Prior anti-cancer therapy before the planned start of AU-007 as follows:,"```json
[
    {
        ""entity"": ""Prior anti-cancer therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""before the planned start of AU-007"",
        ""category"": ""Temporal Constraints""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Drug/Substance"",
        ""name"": ""Prior anti-cancer therapy"",
        ""temporal"": {
            ""end"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""reference_event"": 2
        }
    },
    {
        ""id"": 2,
        ""type"": ""Procedure/Device"",
        ""name"": ""planned start of AU-007""
    }
]
```"
NCT05267626,"Exclusion: Patients who have experienced serious adverse events during prior IL-2 therapy (including but not limited to bowel perforation, gastrointestinal bleeding, arrythmias, myocardial infarction, repetitive seizures).","```json
[
    {
        ""entity"": ""serious adverse events"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""prior IL-2 therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""bowel perforation"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""gastrointestinal bleeding"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""arrythmias"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""myocardial infarction"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""repetitive seizures"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""serious adverse events""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""prior IL-2 therapy""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""bowel perforation""
    },
    {
        ""id"": 4,
        ""type"": ""Condition"",
        ""name"": ""gastrointestinal bleeding""
    },
    {
        ""id"": 5,
        ""type"": ""Condition"",
        ""name"": ""arrythmias""
    },
    {
        ""id"": 6,
        ""type"": ""Condition"",
        ""name"": ""myocardial infarction""
    },
    {
        ""id"": 7,
        ""type"": ""Condition"",
        ""name"": ""repetitive seizures""
    }
]
```"
NCT05267626,Exclusion: Inflammatory process that has not resolved for ≥ 4 weeks from the date of first study dose. Patients with chronic low-grade inflammatory processes such as radiation-induced pneumonitis are excluded regardless of duration,"```json
[
    {
        ""entity"": ""Inflammatory process"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""≥ 4 weeks"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""chronic low-grade inflammatory processes"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""radiation-induced pneumonitis"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Inflammatory process""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""chronic low-grade inflammatory processes"",
        ""temporal"": {
            ""start"": {
                ""number"": 4,
                ""unit"": ""weeks""
            }
        }
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""radiation-induced pneumonitis""
    }
]
```"
NCT05267626,"Exclusion: Second primary invasive malignancy not in remission for ≥ 1 year. Exceptions include non-melanoma locally advanced skin cancer, cervical carcinoma in situ, localized prostate cancer (Gleason score ≤ 7), resected melanoma in situ, or any malignancy considered to be indolent and never required therapy, with the exception of indolent lymphomas","```json
[
    {
        ""entity"": ""Second primary invasive malignancy"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""not in remission for ≥ 1 year"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""non-melanoma locally advanced skin cancer"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""cervical carcinoma in situ"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""localized prostate cancer"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""Gleason score ≤ 7"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""resected melanoma in situ"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""malignancy considered to be indolent and never required therapy"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""indolent lymphomas"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Second primary invasive malignancy"",
        ""temporal"": {
            ""start"": {
                ""number"": 1,
                ""unit"": ""year""
            },
            ""reference_event"": 1
        }
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""non-melanoma locally advanced skin cancer""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""cervical carcinoma in situ""
    },
    {
        ""id"": 4,
        ""type"": ""Condition"",
        ""name"": ""localized prostate cancer""
    },
    {
        ""id"": 5,
        ""type"": ""Condition"",
        ""name"": ""resected melanoma in situ""
    },
    {
        ""id"": 6,
        ""type"": ""Condition"",
        ""name"": ""malignancy considered to be indolent and never required therapy""
    },
    {
        ""id"": 7,
        ""type"": ""Condition"",
        ""name"": ""indolent lymphomas""
    },
    {
        ""id"": 8,
        ""type"": ""Observation"",
        ""name"": ""Gleason score"",
        ""value"": {
            ""range"": {
                ""upper_bound"": 7,
                ""unit"": """"
            }
        }
    }
]
```"
NCT02315066,"Inclusion: Part A1 only: Patients with histological or cytological diagnosis of HNSCC, HCC, melanoma, or clear cell RCC who progressed on or are intolerant to standard therapy, for which no standard therapy is available or who decline standard therapy.","```json
[
    {
        ""entity"": ""histological or cytological diagnosis"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""HNSCC"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""HCC"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""melanoma"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""clear cell RCC"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""progressed"",
        ""category"": ""Qualifier/Modifier""
    },
    {
        ""entity"": ""intolerant"",
        ""category"": ""Qualifier/Modifier""
    },
    {
        ""entity"": ""standard therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""no standard therapy is available"",
        ""category"": ""Qualifier/Modifier""
    },
    {
        ""entity"": ""decline standard therapy"",
        ""category"": ""Qualifier/Modifier""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""histological or cytological diagnosis""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""HNSCC""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""HCC""
    },
    {
        ""id"": 4,
        ""type"": ""Condition"",
        ""name"": ""melanoma""
    },
    {
        ""id"": 5,
        ""type"": ""Condition"",
        ""name"": ""clear cell RCC""
    },
    {
        ""id"": 6,
        ""type"": ""Drug/Substance"",
        ""name"": ""standard therapy""
    }
]
```"
NCT02315066,"Inclusion: Part A2 only: Patients with histological or cytological diagnosis of advanced/metastatic HCC who are treatment naïve and have declined standard of care, or have had at least 1 prior line of systemic therapy. Prior anti PD L1/PD 1 therapy is allowed.","```json
[
    {
        ""entity"": ""histological or cytological diagnosis"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""advanced/metastatic HCC"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""treatment naïve"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""standard of care"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""at least 1 prior line of systemic therapy"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""anti PD L1/PD 1 therapy"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""histological or cytological diagnosis""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""advanced/metastatic HCC""
    },
    {
        ""id"": 3,
        ""type"": ""Procedure/Device"",
        ""name"": ""standard of care""
    },
    {
        ""id"": 4,
        ""type"": ""Drug/Substance"",
        ""name"": ""anti PD L1/PD 1 therapy"",
        ""occurrence"": {
            ""operator"": ""at least"",
            ""number"": 1
        },
        ""temporal"": {
            ""start"": {
                ""number"": 1,
                ""unit"": ""line of systemic therapy""
            }
        }
    }
]
```"
NCT02315066,"Inclusion: Part B1 only: Patients with histological or cytological diagnosis of NSCLC, HNSCC, melanoma, urothelial bladder carcinoma (including renal pelvis, ureters, urinary bladder, and urethra), gastric or squamous cell carcinoma of the uterine cervix who progressed on or are intolerant to standard therapy, for which no standard therapy is available, or who decline standard therapy.","```json
[
    {
        ""entity"": ""histological or cytological diagnosis"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""NSCLC"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""HNSCC"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""melanoma"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""urothelial bladder carcinoma"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""renal pelvis"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""ureters"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""urinary bladder"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""urethra"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""gastric carcinoma"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""squamous cell carcinoma of the uterine cervix"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""progressed on or are intolerant to standard therapy"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""no standard therapy is available"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""decline standard therapy"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""histological or cytological diagnosis""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""NSCLC""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""HNSCC""
    },
    {
        ""id"": 4,
        ""type"": ""Condition"",
        ""name"": ""melanoma""
    },
    {
        ""id"": 5,
        ""type"": ""Condition"",
        ""name"": ""urothelial bladder carcinoma""
    },
    {
        ""id"": 6,
        ""type"": ""Condition"",
        ""name"": ""renal pelvis""
    },
    {
        ""id"": 7,
        ""type"": ""Condition"",
        ""name"": ""ureters""
    },
    {
        ""id"": 8,
        ""type"": ""Condition"",
        ""name"": ""urinary bladder""
    },
    {
        ""id"": 9,
        ""type"": ""Condition"",
        ""name"": ""urethra""
    },
    {
        ""id"": 10,
        ""type"": ""Condition"",
        ""name"": ""gastric carcinoma""
    },
    {
        ""id"": 11,
        ""type"": ""Condition"",
        ""name"": ""squamous cell carcinoma of the uterine cervix""
    },
    {
        ""id"": 12,
        ""type"": ""Condition"",
        ""name"": ""progressed on or are intolerant to standard therapy""
    },
    {
        ""id"": 13,
        ""type"": ""Condition"",
        ""name"": ""no standard therapy is available""
    },
    {
        ""id"": 14,
        ""type"": ""Condition"",
        ""name"": ""decline standard therapy""
    }
]
```"
NCT02315066,Inclusion: Part B2,"```json
[]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Type 2 diabetes mellitus""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""Metformin""
    },
    {
        ""id"": 3,
        ""type"": ""Measurement"",
        ""name"": ""Serum creatinine""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""Chemotherapy""
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""Smoking""
    },
    {
        ""id"": 6,
        ""type"": ""Observation"",
        ""name"": ""30 to 75 years old"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 30,
                ""upper_bound"": 75,
                ""unit"": ""years""
            }
        }
    }
]
```"
NCT02315066,"Inclusion: Ocular melanoma patients with advanced/metastatic disease, or","```json
[
    {
        ""entity"": ""Ocular melanoma"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""advanced/metastatic disease"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Ocular melanoma""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""advanced/metastatic disease""
    }
]
```"
NCT02315066,"Inclusion: Cutaneous/acral melanoma patients with advanced/metastatic disease who have received checkpoint inhibitor (anti PD L1, anti PD 1, or anti CTLA4) based treatment on which disease progressed. \[Note: Checkpoint inhibitor may have been part of a combination therapy, as long as the combination did not contain OX40 or 4 1BB agonist.\] Any questions on prior treatment may be discussed with the Sponsor.","```json
[
    {
        ""entity"": ""Cutaneous/acral melanoma"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""advanced/metastatic disease"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""checkpoint inhibitor"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""anti PD L1"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""anti PD 1"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""anti CTLA4"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""combination therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""OX40 agonist"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""4 1BB agonist"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Cutaneous/acral melanoma""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""advanced/metastatic disease""
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""checkpoint inhibitor""
    },
    {
        ""id"": 4,
        ""type"": ""Drug/Substance"",
        ""name"": ""anti PD L1""
    },
    {
        ""id"": 5,
        ""type"": ""Drug/Substance"",
        ""name"": ""anti PD 1""
    },
    {
        ""id"": 6,
        ""type"": ""Drug/Substance"",
        ""name"": ""anti CTLA4""
    },
    {
        ""id"": 7,
        ""type"": ""Drug/Substance"",
        ""name"": ""combination therapy""
    },
    {
        ""id"": 8,
        ""type"": ""Drug/Substance"",
        ""name"": ""OX40 agonist""
    },
    {
        ""id"": 9,
        ""type"": ""Drug/Substance"",
        ""name"": ""4 1BB agonist""
    }
]
```"
NCT02315066,"Inclusion: Histological or cytological diagnosis of NSCLC with advanced/metastatic disease. Patients must have previously received prior anti PD L1 or anti PD 1 mAb on which disease progressed. \[Note: Previous anti PD L1 or anti PD 1 mAb may have been part of a combination therapy, eg, in combination with chemotherapy, as long as the combination did not contain OX40 or 4 1BB agonist.\]","```json
[
    {
        ""entity"": ""Histological or cytological diagnosis"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""NSCLC"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""advanced/metastatic disease"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""previously received"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""prior anti PD L1 or anti PD 1 mAb"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""disease progressed"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""Previous anti PD L1 or anti PD 1 mAb"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""combination therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""chemotherapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""OX40 or 4 1BB agonist"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Histological or cytological diagnosis""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""NSCLC""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""advanced/metastatic disease""
    },
    {
        ""id"": 4,
        ""type"": ""Drug/Substance"",
        ""name"": ""prior anti PD L1 or anti PD 1 mAb"",
        ""temporal"": {
            ""start"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""end"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""reference_event"": 1
        }
    },
    {
        ""id"": 5,
        ""type"": ""Condition"",
        ""name"": ""disease progressed""
    },
    {
        ""id"": 6,
        ""type"": ""Drug/Substance"",
        ""name"": ""Previous anti PD L1 or anti PD 1 mAb""
    },
    {
        ""id"": 7,
        ""type"": ""Drug/Substance"",
        ""name"": ""combination therapy""
    },
    {
        ""id"": 8,
        ""type"": ""Drug/Substance"",
        ""name"": ""chemotherapy""
    },
    {
        ""id"": 9,
        ""type"": ""Drug/Substance"",
        ""name"": ""OX40 or 4 1BB agonist""
    }
]
```"
NCT02315066,"Inclusion: Performance Status of 0 or 1 - Adequate bone marrow, kidney and liver function","```json
[
    {
        ""entity"": ""Performance Status of 0 or 1"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""Adequate bone marrow function"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""Adequate kidney function"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""Adequate liver function"",
        ""category"": ""Observation""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Performance Status of 0 or 1""
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""Adequate bone marrow function""
    },
    {
        ""id"": 3,
        ""type"": ""Observation"",
        ""name"": ""Adequate kidney function""
    },
    {
        ""id"": 4,
        ""type"": ""Observation"",
        ""name"": ""Adequate liver function""
    }
]
```"
NCT02315066,Exclusion: Brain metastases requiring steroids,"```json
[
    {
        ""entity"": ""Brain metastases"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""requiring steroids"",
        ""category"": ""Qualifier/Modifier""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Brain metastases""
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""requiring steroids""
    }
]
```"
NCT02315066,"Exclusion: Major surgery, Radiation therapy within 4 weeks of starting study treatment (except: palliative radiotherapy to a limited field is allowed after consultation with sponsor's medical monitor at any time during study participation, including during screening), or systemic anti-cancer therapy within 4 weeks of study treatment start (6 weeks for mitomycin C or nitrosoureas)","```json
[
    {
        ""entity"": ""Major surgery"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""Radiation therapy"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""within 4 weeks of starting study treatment"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""palliative radiotherapy to a limited field"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""systemic anti-cancer therapy"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""within 4 weeks of study treatment start"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""6 weeks for mitomycin C or nitrosoureas"",
        ""category"": ""Temporal Constraints""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Procedure/Device"",
        ""name"": ""Major surgery"",
        ""temporal"": {
            ""start"": {
                ""number"": 4,
                ""unit"": ""weeks""
            },
            ""reference_event"": 2
        }
    },
    {
        ""id"": 2,
        ""type"": ""Procedure/Device"",
        ""name"": ""Radiation therapy"",
        ""temporal"": {
            ""start"": {
                ""number"": 4,
                ""unit"": ""weeks""
            },
            ""reference_event"": 3
        }
    },
    {
        ""id"": 3,
        ""type"": ""Procedure/Device"",
        ""name"": ""palliative radiotherapy to a limited field""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""systemic anti-cancer therapy"",
        ""temporal"": {
            ""start"": {
                ""number"": 4,
                ""unit"": ""weeks""
            },
            ""reference_event"": 5
        }
    },
    {
        ""id"": 5,
        ""type"": ""Procedure/Device"",
        ""name"": ""mitomycin C or nitrosoureas"",
        ""temporal"": {
            ""start"": {
                ""number"": 6,
                ""unit"": ""weeks""
            }
        }
    }
]
```"
NCT02315066,"Exclusion: Active and clinically significant bacterial, fungal, or viral infection","```json
[
    {
        ""entity"": ""Active"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""clinically significant"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""bacterial infection"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""fungal infection"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""viral infection"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""bacterial infection""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""fungal infection""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""viral infection""
    }
]
```"
NCT02315066,Exclusion: History of active autoimmune disorders,"```json
[
    {
        ""entity"": ""History"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""active autoimmune disorders"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""History""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""active autoimmune disorders""
    }
]
```"
NCT02315066,Exclusion: History of immune-mediated adverse events requiring immunosuppressive therapy or were grade 3 or higher related to prior immune-modulatory therapy,"```json
[
    {
        ""entity"": ""History of immune-mediated adverse events"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""requiring immunosuppressive therapy"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""grade 3 or higher"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""related to prior immune-modulatory therapy"",
        ""category"": ""Procedure/Device""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""History of immune-mediated adverse events""
    },
    {
        ""id"": 2,
        ""type"": ""Procedure/Device"",
        ""name"": ""requiring immunosuppressive therapy""
    },
    {
        ""id"": 3,
        ""type"": ""Procedure/Device"",
        ""name"": ""related to prior immune-modulatory therapy""
    }
]
```"
NCT02315066,Exclusion: Prior treatment with an OX40 agonist and 4-1BB agonist (for Part B1/B2),"```json
[
    {
        ""entity"": ""Prior treatment"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""OX40 agonist"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""4-1BB agonist"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Drug/Substance"",
        ""name"": ""OX40 agonist""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""4-1BB agonist""
    }
]
```"
NCT02315066,Exclusion: Prior anthracycline treatment and at risk of cardiac failure (New York Heart Association Class 2),"```json
[
    {
        ""entity"": ""Prior anthracycline treatment"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""at risk of cardiac failure"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""New York Heart Association Class 2"",
        ""category"": ""Measurement""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Drug/Substance"",
        ""name"": ""Prior anthracycline treatment""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""at risk of cardiac failure""
    }
]
```"
NCT02595866,"Inclusion: Histologically or cytologically proven metastatic or locally advanced tumors for which no standard therapy exists, or where standard therapy has failed, or in patients otherwise ineligible for standard therapy, or for an indication that anti-PD-1 therapy has been shown to be effective in studies in HIV-uninfected participants; disease-specific criteria will be applied for certain common cancers and cancers strongly associated with HIV; however, enrollment will not be confined to these tumors","```json
[
    {
        ""entity"": ""Histologically or cytologically proven metastatic or locally advanced tumors"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""standard therapy"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""anti-PD-1 therapy"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""HIV-uninfected participants"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""disease-specific criteria"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""common cancers"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""cancers strongly associated with HIV"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Histologically or cytologically proven metastatic or locally advanced tumors""
    },
    {
        ""id"": 2,
        ""type"": ""Procedure/Device"",
        ""name"": ""standard therapy""
    },
    {
        ""id"": 3,
        ""type"": ""Procedure/Device"",
        ""name"": ""anti-PD-1 therapy""
    },
    {
        ""id"": 4,
        ""type"": ""Condition"",
        ""name"": ""HIV-uninfected participants""
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""disease-specific criteria""
    },
    {
        ""id"": 6,
        ""type"": ""Condition"",
        ""name"": ""common cancers""
    },
    {
        ""id"": 7,
        ""type"": ""Condition"",
        ""name"": ""cancers strongly associated with HIV""
    }
]
```"
NCT02595866,Inclusion: Non-small cell lung cancer (NSCLC),"```json
[
    {
        ""entity"": ""Non-small cell lung cancer"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""NSCLC"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Non-small cell lung cancer""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""NSCLC""
    }
]
```"
NCT02595866,Inclusion: AIDS-related non-Hodgkin lymphoma and other non-Hodgkin lymphoma,"```json
[
    {
        ""entity"": ""AIDS-related non-Hodgkin lymphoma"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""non-Hodgkin lymphoma"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""AIDS-related non-Hodgkin lymphoma""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""non-Hodgkin lymphoma""
    }
]
```"
NCT02595866,Inclusion: Classical Hodgkin lymphoma,"```json
[
    {
        ""entity"": ""Classical Hodgkin lymphoma"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Classical Hodgkin lymphoma""
    }
]
```"
NCT02595866,Inclusion: Hepatocellular carcinoma (HCC),"```json
[
    {
        ""entity"": ""Hepatocellular carcinoma"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""HCC"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Hepatocellular carcinoma""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""HCC""
    }
]
```"
NCT02595866,Inclusion: Kaposi sarcoma impacting physical and/or psychological wellbeing and not amenable to local therapy. Patients who have received prior therapy and treatment naive patients are both potentially eligible to participate.,"```json
[
    {
        ""entity"": ""Kaposi sarcoma"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""impacting physical and/or psychological wellbeing"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""not amenable to local therapy"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""prior therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""treatment naive patients"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Kaposi sarcoma""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""impacting physical and/or psychological wellbeing""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""not amenable to local therapy""
    },
    {
        ""id"": 4,
        ""type"": ""Drug/Substance"",
        ""name"": ""prior therapy""
    },
    {
        ""id"": 5,
        ""type"": ""Condition"",
        ""name"": ""treatment naive patients""
    }
]
```"
NCT02595866,Inclusion: Melanoma,"```json
[
    {
        ""entity"": ""Melanoma"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Melanoma""
    }
]
```"
NCT02595866,"Inclusion: Available pretreatment biopsy, either fresh (optimal) or archival (acceptable)","```json
[
    {
        ""entity"": ""pretreatment biopsy"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""fresh"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""archival"",
        ""category"": ""Qualifiers/Modifiers""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Procedure/Device"",
        ""name"": ""pretreatment biopsy""
    }
]
```"
NCT02595866,"Inclusion: Resolution of any adverse events (AEs) from prior treatments must be resolved to baseline or grade =\< 1 at enrollment (with the exception of alopecia), neuropathy, and ototoxicity (i.e., AEs that are not expected to improve within the washout period)","```json
[
    {
        ""entity"": ""Resolution of any adverse events (AEs) from prior treatments"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""baseline"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""grade =< 1"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""enrollment"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""alopecia"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""neuropathy"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""ototoxicity"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""AEs that are not expected to improve within the washout period"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Resolution of any adverse events (AEs) from prior treatments"",
        ""value"": {
            ""qualitative"": ""grade =< 1""
        },
        ""temporal"": {
            ""start"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""end"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""reference_event"": 2
        }
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""baseline"",
        ""temporal"": {
            ""start"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""end"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""reference_event"": 3
        }
    },
    {
        ""id"": 3,
        ""type"": ""Observation"",
        ""name"": ""enrollment""
    },
    {
        ""id"": 4,
        ""type"": ""Condition"",
        ""name"": ""alopecia""
    },
    {
        ""id"": 5,
        ""type"": ""Condition"",
        ""name"": ""neuropathy""
    },
    {
        ""id"": 6,
        ""type"": ""Condition"",
        ""name"": ""ototoxicity""
    },
    {
        ""id"": 7,
        ""type"": ""Condition"",
        ""name"": ""AEs that are not expected to improve within the washout period""
    }
]
```"
NCT02595866,"Inclusion: On an effective combination cART regimen, generally a 3-drug regimen based on Department of Health and Human Services (DHHS) treatment guidelines","```json
[
    {
        ""entity"": ""combination cART regimen"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""3-drug regimen"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""Department of Health and Human Services (DHHS) treatment guidelines"",
        ""category"": ""Observation""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Drug/Substance"",
        ""name"": ""combination cART regimen""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""3-drug regimen""
    },
    {
        ""id"": 3,
        ""type"": ""Observation"",
        ""name"": ""Department of Health and Human Services (DHHS) treatment guidelines""
    }
]
```"
NCT02595866,Inclusion: CD4+ T-cell count \>= 50 cells/uL,"```json
[
    {
        ""entity"": ""CD4+ T-cell count"",
        ""category"": ""Observation""
    },
    {
        ""entity"": "">= 50 cells/uL"",
        ""category"": ""Measurement""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""CD4+ T-cell count"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 50,
                ""upper_bound"": null,
                ""unit"": ""cells/uL""
            }
        }
    }
]
```"
NCT02595866,Inclusion: Patients must have marrow function and organ function as defined below,"```json
[
    {
        ""entity"": ""marrow function"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""organ function"",
        ""category"": ""Observation""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""marrow function""
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""organ function""
    }
]
```"
NCT02595866,Inclusion: Leukocytes no lower limit,"```json
[
    {
        ""entity"": ""Leukocytes"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""no lower limit"",
        ""category"": ""Measurement""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Leukocytes"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 0,
                ""upper_bound"": null,
                ""unit"": null
            }
        }
    }
]
```"
NCT02595866,Inclusion: Absolute neutrophil count \> 500/mcL,"```json
[
    {
        ""entity"": ""Absolute neutrophil count"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""> 500/mcL"",
        ""category"": ""Measurement""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Absolute neutrophil count"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 500,
                ""upper_bound"": null,
                ""unit"": ""mcL""
            }
        }
    }
]
```"
NCT02595866,"Inclusion: Platelets \> 50,000/mcL","```json
[
    {
        ""entity"": ""Platelets"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""> 50,000/mcL"",
        ""category"": ""Measurement""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Platelets"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 50000,
                ""upper_bound"": null,
                ""unit"": ""mcL""
            }
        }
    }
]
```"
NCT02595866,Inclusion: Hemoglobin \> 9 g/dL,"```json
[
    {
        ""entity"": ""Hemoglobin"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""> 9 g/dL"",
        ""category"": ""Measurement""
    }
]
```","```python
def extract_events(inputs: Dict[str, Any]) -> str:
    """"""
    This function is used to identify and extract structured events and attributes related to the specified entities from the input text.
    The entities, along with their types and names, have been identified in a previous step and are provided for reference.

    The function takes a dictionary of `inputs` as an argument, which contains the following keys:
    - 'input_text': the input eligibility criteria in text format
    - 'entities': a list of entities, each containing the type and name of an entity identified in the input text
        e.g., [""Condition: Type 2 diabetes mellitus"", ""Drug/Substance: Metformin"", ""Measurement: Serum creatinine"", ""Procedure/Device: Chemotherapy"", ""Observation: Smoking"", ""Observation: 30 to 75 years old"", ...]

    The function should return a list of dictionaries, each containing the extracted events and attributes for the specified entities.
    - Event entity types include: `Condition`, `Observation`, `Procedure/Device`, `Drug/Substance`.
    - Attribute entities include: `Measurement`, `Temporal Constraints`, `Qualifiers/Modifiers`.

    The formats of the target extracted events are as follows:


    Observation:
    {
        ""id"": int, \\ the unique identifier of the event, starting from 1 to N
        ""type"":""Observation"",
        ""name"": str, \\ the name of the observation
        ""occurrence"": {
            ""operator"": str, \\ the operator of the occurrence, in [""at least"", ""at most"", ""exactly""]
            ""number"": int, \\ the number of occurrence
        },
        ""temporal"": {
            ""start"": {
                ""number"": int, \\ the number of days/months/years/etc before the reference event
                ""unit"": str, \\ the unit of the temporal, in [""days"", ""weeks"", ""months"", ""years""]
            },
            ""end"":{
                ""number"": int, \\ the number of days/months/years/etc after the reference event
                ""unit"": str, \\ the unit of the temporal, in [""days"", ""weeks"", ""months"", ""years""]
            },
            ""reference_event"": int, \\ the reference event id for the start and end window
        },
        ""value"":{
            ""range"": {
                ""lower_bound"": float, \\ the lower bound of the measurement value
                ""upper_bound"": float, \\ the upper bound of the measurement value
                ""unit"": str, \\ the unit of the measurement value
            },
            ""qualitative"": str, \\  the qualitative value of the measurement, e.g., ""positive"", ""negative"", ""normal"", ""abnormal"", etc.
        },
    }

    Condition:
    {
        ""id"": int, \\ the unique identifier of the event, starting from 1 to N
        ""type"":""Condition"", \\ the type of the entity
        ""name"": str, \\ the name of the condition
        ""occurrence"": {
            ""operator"": str, \\ the operator of the occurrence, in [""at least"", ""at most"", ""exactly""]
            ""number"": int, \\ the number of occurrences 
            }},
        ""temporal"": {
            ""start"": {
                ""number"": int, \\ the number of days/months/years/etc before the reference event
                ""unit"": str, \\ the unit of the temporal, in [""days"", ""weeks"", ""months"", ""years""]
            },
            ""end"":{
                ""number"": int, \\ the number of days/months/years/etc after the reference event
                ""unit"": str, \\ the unit of the temporal, in [""days"", ""weeks"", ""months"", ""years""]
            },
            ""reference_event"": int, \\ the reference event id for the start and end window
        }
    }

    Drug/Substance:
    {
        ""id"": int, \\ the unique identifier of the event, starting from 1 to N
        ""type"":""Drug/Substance"",
        ""name"": str, \\ the name of the drug
        ""occurrence"": {
            ""operator"": str, \\ the operator of the occurrence, in [""at least"", ""at most"", ""exactly""]
            ""number"": int, \\ the number of occurrence
        },
        ""temporal"": {
            ""start"": {
                ""number"": int, \\ the number of days/months/years/etc before the reference event
                ""unit"": str, \\ the unit of the temporal, in [""days"", ""weeks"", ""months"", ""years""]
            },
            ""end"":{
                ""number"": int, \\ the number of days/months/years/etc after the reference event
                ""unit"": str, \\ the unit of the temporal, in [""days"", ""weeks"", ""months"", ""years""]
            },
            ""reference_event"": int, \\ the reference event id for the start and end window
        }
    }


    Procedure/Device:
    {
        ""id"": int, \\ the unique identifier of the event, starting from 1 to N
        ""type"":""Procedure/Device"",
        ""name"": str, \\ the name of the procedure
        ""occurrence"": {
            ""operator"": str, \\ the operator of the occurrence, in [""at least"", ""at most"", ""exactly""]
            ""number"": int, \\ the number of occurrence
        },
        ""temporal"": {
            ""start"": {
                ""number"": int, \\ the number of days/months/years/etc before the reference event
                ""unit"": str, \\ the unit of the temporal, in [""days"", ""weeks"", ""months"", ""years""]
            },
            ""end"":{
                ""number"": int, \\ the number of days/months/years/etc after the reference event
                ""unit"": str, \\ the unit of the temporal, in [""days"", ""weeks"", ""months"", ""years""]
            },
            ""reference_event"": int, \\ the reference event id for the start and end window
        }
    }}

    IMPORTANT: 
    - for all the events, the fields 'id', 'type', 'name' are mandatory, the other fields are optional and should be included only if they are present in the input text.
    - for all the events, the field 'type' must be one of the following: 'Condition', 'Observation', 'Procedure/Device', 'Drug/Substance'.

    The function should return a syntactically correct JSON format string that contains a list of the extracted events, each event should be one of the above formats.
    The output is wrapped within  ```json and ``` tags, for example:
    ```json
    [
        {
            ""id"": 1, \\ the unique identifier of the event, starting from 1 to N
            ""type"":""Observation"", \\ the type of the entity
            ""name"": ""age"", \\ the name of the observation
            ""value"":{
                ""range"": {
                    ""lower_bound"": float, \\ the lower bound of the age value
                    ""upper_bound"": float, \\ the upper bound of the age value
                    ""unit"": str, \\ the unit of the age value
                }},
        },
        ... \\ other events
    ]
    ```

    Returns:
    - str: a JSON format string that contains a list of the extracted events, wrapped by ```json and ``` tags
    """"""
    input_text = inputs[""input_text""]
    entities = inputs[""entities""]

    events = []
    event_id = 1

    for entity in entities:
        if entity[""category""] == ""Observation"":
            event = {
                ""id"": event_id,
                ""type"": ""Observation"",
                ""name"": entity[""entity""]
            }
            event_id += 1
            events.append(event)
        elif entity[""category""] == ""Measurement"":
            if events and events[-1][""type""] == ""Observation"":
                measurement = entity[""entity""]
                if "">"" in measurement:
                    operator = ""at least""
                    value = float(measurement.split("">"")[1].strip().split()[0])
                    unit = measurement.split("">"")[1].strip().split()[1]
                elif ""<"" in measurement:
                    operator = ""at most""
                    value = float(measurement.split(""<"")[1].strip().split()[0])
                    unit = measurement.split(""<"")[1].strip().split()[1]
                else:
                    operator = ""exactly""
                    value = float(measurement.split()[0])
                    unit = measurement.split()[1]

                events[-1][""value""] = {
                    ""range"": {
                        ""lower_bound"": value if operator == ""at least"" else None,
                        ""upper_bound"": value if operator == ""at most"" else None,
                        ""unit"": unit
                    }
                }

    return f""""""```json
{json.dumps(events, indent=4)}
```""""""
```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Hemoglobin"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 9.0,
                ""upper_bound"": null,
                ""unit"": ""g/dL""
            }
        }
    }
]
```"
NCT02595866,Inclusion: Total bilirubin \< 1.5 X upper limit of normal (ULN); or \< 3 x institutional ULN for Gilbert's syndrome or HIV protease inhibitors; or \< 5 x ULN and direct bilirubin \< 0.7 mg/dL for patients on atazanavir containing HIV regimen,"```json
[
    {
        ""entity"": ""Total bilirubin"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""< 1.5 X upper limit of normal (ULN)"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""< 3 x institutional ULN"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""Gilbert's syndrome"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""HIV protease inhibitors"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""< 5 x ULN"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""direct bilirubin"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""< 0.7 mg/dL"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""patients on atazanavir containing HIV regimen"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Total bilirubin"",
        ""value"": {
            ""range"": {
                ""upper_bound"": 1.5,
                ""unit"": ""X upper limit of normal (ULN)""
            }
        }
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""Gilbert's syndrome""
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""HIV protease inhibitors""
    },
    {
        ""id"": 4,
        ""type"": ""Observation"",
        ""name"": ""direct bilirubin"",
        ""value"": {
            ""range"": {
                ""upper_bound"": 0.7,
                ""unit"": ""mg/dL""
            }
        }
    },
    {
        ""id"": 5,
        ""type"": ""Drug/Substance"",
        ""name"": ""patients on atazanavir containing HIV regimen""
    }
]
```"
NCT02595866,Inclusion: Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) \< 2.5 X institutional ULN,"```json
[
    {
        ""entity"": ""Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""< 2.5 X institutional ULN"",
        ""category"": ""Measurement""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])"",
        ""value"": {
            ""range"": {
                ""upper_bound"": 2.5,
                ""unit"": ""X institutional ULN""
            }
        }
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])"",
        ""value"": {
            ""range"": {
                ""upper_bound"": 2.5,
                ""unit"": ""X institutional ULN""
            }
        }
    }
]
```"
NCT02595866,Inclusion: Creatine kinase \< 5 X institutional ULN,"```json
[
    {
        ""entity"": ""Creatine kinase"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""< 5 X institutional ULN"",
        ""category"": ""Measurement""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Creatine kinase"",
        ""value"": {
            ""range"": {
                ""upper_bound"": 5,
                ""unit"": ""X institutional ULN""
            }
        }
    }
]
```"
NCT02595866,Inclusion: Serum creatinine \< 2.5 X institutional ULN OR measured or calculated\* creatinine clearance (CrCl) (glomerular filtration rate \[GFR\] can also be used in place of creatinine or CrCl) \>= 30 mL/min for subject with creatinine levels \> 2.5 X institutional ULN,"```json
[
    {
        ""entity"": ""Serum creatinine"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""< 2.5 X institutional ULN"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""measured or calculated creatinine clearance (CrCl)"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""glomerular filtration rate (GFR)"",
        ""category"": ""Observation""
    },
    {
        ""entity"": "">= 30 mL/min"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""creatinine levels > 2.5 X institutional ULN"",
        ""category"": ""Measurement""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Serum creatinine"",
        ""value"": {
            ""range"": {
                ""upper_bound"": 2.5,
                ""unit"": ""X institutional ULN""
            }
        }
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""measured or calculated creatinine clearance (CrCl)""
    },
    {
        ""id"": 3,
        ""type"": ""Observation"",
        ""name"": ""glomerular filtration rate (GFR)""
    },
    {
        ""id"": 4,
        ""type"": ""Observation"",
        ""name"": ""creatinine levels"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 2.5,
                ""unit"": ""X institutional ULN""
            }
        }
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""glomerular filtration rate (GFR)"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 30,
                ""unit"": ""mL/min""
            }
        }
    }
]
```"
NCT02595866,Inclusion: Thyroid stimulating hormone (TSH) within institutional limits (ie: normal); if TSH is greater or less than institutional limits patients may participate if their T4 is within normal limits (WNL); patients may be on a stable dose of replacement thyroid medication; dose adjustments are allowed if needed,"```json
[
    {
        ""entity"": ""Thyroid stimulating hormone (TSH)"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""within institutional limits"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""normal"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""TSH"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""greater or less than institutional limits"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""T4"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""within normal limits (WNL)"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""stable dose"",
        ""category"": ""Qualifier/Modifier""
    },
    {
        ""entity"": ""replacement thyroid medication"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""dose adjustments"",
        ""category"": ""Procedure/Device""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Thyroid stimulating hormone (TSH)"",
        ""value"": {
            ""qualitative"": ""normal""
        }
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""TSH"",
        ""value"": {
            ""qualitative"": ""greater or less than institutional limits""
        }
    },
    {
        ""id"": 3,
        ""type"": ""Observation"",
        ""name"": ""T4"",
        ""value"": {
            ""qualitative"": ""within normal limits (WNL)""
        }
    },
    {
        ""id"": 4,
        ""type"": ""Drug/Substance"",
        ""name"": ""replacement thyroid medication"",
        ""occurrence"": {
            ""operator"": ""exactly"",
            ""number"": 1
        }
    },
    {
        ""id"": 5,
        ""type"": ""Procedure/Device"",
        ""name"": ""dose adjustments"",
        ""occurrence"": {
            ""operator"": ""exactly"",
            ""number"": 1
        }
    }
]
```"
NCT02595866,Inclusion: Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 1,"```json
[
    {
        ""entity"": ""Eastern Cooperative Oncology Group (ECOG) performance score"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""0 to 1"",
        ""category"": ""Measurement""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Eastern Cooperative Oncology Group (ECOG) performance score"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 0,
                ""upper_bound"": 1,
                ""unit"": """"
            }
        }
    }
]
```"
NCT02595866,Inclusion: At least 2 weeks from end of chemotherapy with resolution of neutropenia to above level,"```json
[
    {
        ""entity"": ""at least 2 weeks"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""end of chemotherapy"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""resolution of neutropenia"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""above level"",
        ""category"": ""Measurement""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""resolution of neutropenia""
    }
]
```"
NCT02595866,Inclusion: At least 2 weeks from end of radiation therapy,"```json
[
    {
        ""entity"": ""at least 2 weeks"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""end of radiation therapy"",
        ""category"": ""Temporal Constraints""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Temporal Constraints"",
        ""name"": ""at least 2 weeks"",
        ""temporal"": {
            ""start"": {
                ""number"": 2,
                ""unit"": ""weeks""
            },
            ""reference_event"": ""end of radiation therapy""
        }
    }
]
```"
NCT02595866,Inclusion: At least 4 weeks from end of monoclonal antibody therapy,"```json
[
    {
        ""entity"": ""at least 4 weeks"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""monoclonal antibody therapy"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Drug/Substance"",
        ""name"": ""monoclonal antibody therapy"",
        ""temporal"": {
            ""start"": {
                ""number"": 4,
                ""unit"": ""weeks""
            }
        }
    }
]
```"
NCT02595866,Inclusion: At least 2 weeks from end of targeted therapy,"```json
[
    {
        ""entity"": ""at least 2 weeks"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""end of targeted therapy"",
        ""category"": ""Temporal Constraints""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Temporal Constraints"",
        ""name"": ""at least 2 weeks"",
        ""temporal"": {
            ""start"": {
                ""number"": 2,
                ""unit"": ""weeks""
            },
            ""reference_event"": ""start of the study""
        }
    },
    {
        ""id"": 2,
        ""type"": ""Temporal Constraints"",
        ""name"": ""end of targeted therapy"",
        ""temporal"": {
            ""end"": {
                ""number"": 0,
                ""unit"": ""days""
            },
            ""reference_event"": ""end of targeted therapy""
        }
    }
]
```"
NCT02595866,"Inclusion: Female patients of childbearing potential must have a negative urine or serum pregnancy within 72 hours before receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required","```json
[
    {
        ""entity"": ""Female patients of childbearing potential"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""negative"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""urine or serum pregnancy"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""within 72 hours before receiving the first dose of study medication"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""urine test"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""positive"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""serum pregnancy test"",
        ""category"": ""Observation""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Female patients of childbearing potential""
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""urine or serum pregnancy"",
        ""temporal"": {
            ""start"": {
                ""number"": 72,
                ""unit"": ""hours""
            },
            ""reference_event"": 3
        },
        ""value"": {
            ""qualitative"": ""negative""
        }
    },
    {
        ""id"": 3,
        ""type"": ""Observation"",
        ""name"": ""urine test"",
        ""value"": {
            ""qualitative"": ""positive""
        }
    },
    {
        ""id"": 4,
        ""type"": ""Observation"",
        ""name"": ""serum pregnancy test"",
        ""value"": {
            ""qualitative"": ""positive""
        }
    }
]
```"
NCT02595866,"Inclusion: Men treated or enrolled on this protocol must agree to use 2 adequate methods of contraception starting with the screening visit, for the duration of study participation, and through 120 days after the last dose of MK-3475 administration","```json
[]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Type 2 diabetes mellitus""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""Metformin""
    },
    {
        ""id"": 3,
        ""type"": ""Measurement"",
        ""name"": ""Serum creatinine""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""Chemotherapy""
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""Smoking""
    },
    {
        ""id"": 6,
        ""type"": ""Observation"",
        ""name"": ""30 to 75 years old"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 30,
                ""upper_bound"": 75,
                ""unit"": ""years""
            }
        }
    }
]
```"
NCT02595866,Inclusion: No prior treatment with anti-PD-1 or anti-PD-L1,"```json
[
    {
        ""entity"": ""prior"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""treatment"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""anti-PD-1"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""anti-PD-L1"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Procedure/Device"",
        ""name"": ""treatment""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""anti-PD-1""
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""anti-PD-L1""
    }
]
```"
NCT02595866,Inclusion: Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 or other tumor-specific criteria or disease assessable by physical exam or other methods if not measurable by RECIST,"```json
[
    {
        ""entity"": ""Measurable disease"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""tumor-specific criteria"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""disease assessable by physical exam"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""other methods"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""not measurable by RECIST"",
        ""category"": ""Qualifier/Modifier""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Measurable disease""
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1""
    },
    {
        ""id"": 3,
        ""type"": ""Observation"",
        ""name"": ""tumor-specific criteria""
    },
    {
        ""id"": 4,
        ""type"": ""Condition"",
        ""name"": ""disease assessable by physical exam""
    },
    {
        ""id"": 5,
        ""type"": ""Procedure/Device"",
        ""name"": ""other methods""
    }
]
```"
NCT02595866,"Inclusion: Baseline tumor tissue, either fresh (preferred) or from paraffin block/unstained slides if contemporary biopsy is unsafe or not otherwise obtainable from the primary tumor site or metastatic site to be available for use on correlative studies","```json
[
    {
        ""entity"": ""Baseline tumor tissue"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""fresh"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""paraffin block"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""unstained slides"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""contemporary biopsy"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""unsafe"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""primary tumor site"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""metastatic site"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""correlative studies"",
        ""category"": ""Procedure/Device""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Baseline tumor tissue""
    },
    {
        ""id"": 2,
        ""type"": ""Procedure/Device"",
        ""name"": ""paraffin block""
    },
    {
        ""id"": 3,
        ""type"": ""Procedure/Device"",
        ""name"": ""unstained slides""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""contemporary biopsy""
    },
    {
        ""id"": 5,
        ""type"": ""Condition"",
        ""name"": ""primary tumor site""
    },
    {
        ""id"": 6,
        ""type"": ""Condition"",
        ""name"": ""metastatic site""
    },
    {
        ""id"": 7,
        ""type"": ""Procedure/Device"",
        ""name"": ""correlative studies""
    }
]
```"
NCT02595866,Inclusion: Age \>= 18 years,"```json
[
    {
        ""entity"": ""Age"",
        ""category"": ""Observation""
    },
    {
        ""entity"": "">= 18 years"",
        ""category"": ""Measurement""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Age"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 18,
                ""upper_bound"": null,
                ""unit"": ""years""
            }
        }
    }
]
```"
NCT02595866,Inclusion: Ability to understand and willingness to sign a written informed consent document,"```json
[]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Type 2 diabetes mellitus""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""Metformin""
    },
    {
        ""id"": 3,
        ""type"": ""Measurement"",
        ""name"": ""Serum creatinine""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""Chemotherapy""
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""Smoking""
    },
    {
        ""id"": 6,
        ""type"": ""Observation"",
        ""name"": ""30 to 75 years old""
    }
]
```"
NCT02595866,Exclusion: Active systemic immunosuppressive therapy,"```json
[
    {
        ""entity"": ""Active"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""systemic immunosuppressive therapy"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Drug/Substance"",
        ""name"": ""systemic immunosuppressive therapy"",
        ""occurrence"": {
            ""operator"": ""at least"",
            ""number"": 1
        }
    }
]
```"
NCT02595866,Exclusion: Systemic steroid therapy or steroid therapy that cannot be discontinued with more than 7 consecutive days of steroids within the prior 2 weeks,"```json
[
    {
        ""entity"": ""Systemic steroid therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""steroid therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""more than 7 consecutive days"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""steroids"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""within the prior 2 weeks"",
        ""category"": ""Temporal Constraints""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Drug/Substance"",
        ""name"": ""Systemic steroid therapy"",
        ""temporal"": {
            ""start"": {
                ""number"": 2,
                ""unit"": ""weeks""
            },
            ""reference_event"": 0
        }
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""steroid therapy"",
        ""temporal"": {
            ""start"": {
                ""number"": 2,
                ""unit"": ""weeks""
            },
            ""reference_event"": 0
        }
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""steroids"",
        ""temporal"": {
            ""start"": {
                ""number"": 2,
                ""unit"": ""weeks""
            },
            ""reference_event"": 0
        }
    }
]
```"
NCT02595866,Exclusion: Current or history of systemic autoimmune disease requiring systemic therapy,"```json
[
    {
        ""entity"": ""Current or history of systemic autoimmune disease"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""requiring systemic therapy"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Current or history of systemic autoimmune disease""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""requiring systemic therapy""
    }
]
```"
NCT02595866,Exclusion: Grade 3 or 4 immune related toxicity associated with prior ipilimumab therapy that has not resolved to grade 0 or 1,"```json
[
    {
        ""entity"": ""Grade 3 or 4"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""immune related toxicity"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""prior ipilimumab therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""not resolved to grade 0 or 1"",
        ""category"": ""Measurement""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""immune related toxicity""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""prior ipilimumab therapy""
    }
]
```"
NCT02595866,"Exclusion: Cardiovascular disease that meets one of the following: congestive heart failure (New York Heart Association class III or IV), active angina pectoris, or recent myocardial infarction (within the last 6 months)","```json
[
    {
        ""entity"": ""Cardiovascular disease"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""congestive heart failure"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""New York Heart Association class III or IV"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""active angina pectoris"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""recent myocardial infarction"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""within the last 6 months"",
        ""category"": ""Temporal Constraints""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Cardiovascular disease""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""congestive heart failure""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""active angina pectoris""
    },
    {
        ""id"": 4,
        ""type"": ""Condition"",
        ""name"": ""recent myocardial infarction"",
        ""temporal"": {
            ""start"": {
                ""number"": 6,
                ""unit"": ""months""
            },
            ""reference_event"": 0
        }
    }
]
```"
NCT02595866,Exclusion: Active tuberculosis (TB) or atypical mycobacterial infection:,"```json
[
    {
        ""entity"": ""Active tuberculosis (TB)"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""atypical mycobacterial infection"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Active tuberculosis (TB)""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""atypical mycobacterial infection""
    }
]
```"
NCT02595866,Exclusion: Cirrhosis with Child-Pugh score of B or C,"```json
[
    {
        ""entity"": ""Cirrhosis"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""Child-Pugh score of B or C"",
        ""category"": ""Observation""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Cirrhosis""
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""Child-Pugh score of B or C""
    }
]
```"
NCT02595866,"Exclusion: Uncontrolled hepatitis B virus (HBV) infection, defined as acute liver failure or protracted, severe course, as indicated by total bilirubin \> 3 mg/dL (or direct bilirubin \> 1.5 mg/dL), international normalized ratio \> 1.5, encephalopathy, or ascites","```json
[
    {
        ""entity"": ""Uncontrolled"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""hepatitis B virus (HBV) infection"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""acute liver failure"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""protracted, severe course"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""total bilirubin"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""> 3 mg/dL"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""direct bilirubin"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""> 1.5 mg/dL"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""international normalized ratio"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""> 1.5"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""encephalopathy"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""ascites"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""hepatitis B virus (HBV) infection""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""acute liver failure""
    },
    {
        ""id"": 3,
        ""type"": ""Observation"",
        ""name"": ""total bilirubin"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 3.0,
                ""upper_bound"": null,
                ""unit"": ""mg/dL""
            }
        }
    },
    {
        ""id"": 4,
        ""type"": ""Observation"",
        ""name"": ""direct bilirubin"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 1.5,
                ""upper_bound"": null,
                ""unit"": ""mg/dL""
            }
        }
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""international normalized ratio"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 1.5,
                ""upper_bound"": null,
                ""unit"": """"
            }
        }
    },
    {
        ""id"": 6,
        ""type"": ""Condition"",
        ""name"": ""encephalopathy""
    },
    {
        ""id"": 7,
        ""type"": ""Condition"",
        ""name"": ""ascites""
    }
]
```"
NCT02595866,"Exclusion: Uncontrolled hepatitis C virus (HCV) infection, defined as plasma HCV RNA detectable by PCR","```json
[
    {
        ""entity"": ""Uncontrolled"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""hepatitis C virus (HCV) infection"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""plasma HCV RNA"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""detectable by PCR"",
        ""category"": ""Qualifiers/Modifiers""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""hepatitis C virus (HCV) infection""
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""plasma HCV RNA"",
        ""value"": {
            ""qualitative"": ""detectable by PCR""
        }
    }
]
```"
NCT02595866,Exclusion: Patients who are receiving any other investigational agents for cancer,"```json
[
    {
        ""entity"": ""investigational agents"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""cancer"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Drug/Substance"",
        ""name"": ""investigational agents""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""cancer""
    }
]
```"
NCT02595866,"Exclusion: Extensive active brain disease including symptomatic brain metastases or the presence of leptomeningeal disease, and all patients with infratentorial tumors","```json
[
    {
        ""entity"": ""Extensive active brain disease"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""symptomatic brain metastases"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""leptomeningeal disease"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""infratentorial tumors"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Extensive active brain disease""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""symptomatic brain metastases""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""leptomeningeal disease""
    },
    {
        ""id"": 4,
        ""type"": ""Condition"",
        ""name"": ""infratentorial tumors""
    }
]
```"
NCT02595866,Exclusion: Pregnancy or nursing or unwilling to take adequate birth control during therapy,"```json
[
    {
        ""entity"": ""Pregnancy"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""nursing"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Pregnancy""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""nursing""
    }
]
```"
NCT02595866,"Exclusion: Prior organ allograft or allogeneic transplantation, if the transplanted tissue is still in place","```json
[
    {
        ""entity"": ""Prior"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""organ allograft"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""allogeneic transplantation"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""transplanted tissue"",
        ""category"": ""Procedure/Device""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Procedure/Device"",
        ""name"": ""organ allograft""
    },
    {
        ""id"": 2,
        ""type"": ""Procedure/Device"",
        ""name"": ""allogeneic transplantation""
    },
    {
        ""id"": 3,
        ""type"": ""Procedure/Device"",
        ""name"": ""transplanted tissue""
    }
]
```"
NCT02595866,"Exclusion: Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia","```json
[
    {
        ""entity"": ""Uncontrolled"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""intercurrent illness"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""ongoing or active infection"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""symptomatic congestive heart failure"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""unstable angina pectoris"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""cardiac arrhythmia"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""intercurrent illness""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""ongoing or active infection""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""symptomatic congestive heart failure""
    },
    {
        ""id"": 4,
        ""type"": ""Condition"",
        ""name"": ""unstable angina pectoris""
    },
    {
        ""id"": 5,
        ""type"": ""Condition"",
        ""name"": ""cardiac arrhythmia""
    }
]
```"
NCT02595866,"Exclusion: Medical or psychiatric illness or social situations that would, in the opinion of the investigator, preclude participation in the study or the ability of patients to provide informed consent for themselves","```json
[
    {
        ""entity"": ""Medical illness"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""psychiatric illness"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Medical illness""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""psychiatric illness""
    }
]
```"
NCT02595866,Exclusion: Clinically significant lung disease including known history or evidence of interstitial lung disease or chronic obstructive pulmonary disease (COPD) that requires oxygen therapy,"```json
[
    {
        ""entity"": ""Clinically significant"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""lung disease"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""known history or evidence of interstitial lung disease"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""chronic obstructive pulmonary disease (COPD)"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""requires oxygen therapy"",
        ""category"": ""Procedure/Device""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""lung disease""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""known history or evidence of interstitial lung disease""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""chronic obstructive pulmonary disease (COPD)""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""requires oxygen therapy""
    }
]
```"
NCT02595866,Exclusion: Active non-infectious pneumonitis \>= grade 2 or history of grade 3 non-infectious pneumonitis requiring steroids within the past 12 months; or any history of grade 4 non-infectious pneumonitis,"```json
[
    {
        ""entity"": ""Active non-infectious pneumonitis"",
        ""category"": ""Condition""
    },
    {
        ""entity"": "">= grade 2"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""history of grade 3 non-infectious pneumonitis"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""requiring steroids"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""within the past 12 months"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""history of grade 4 non-infectious pneumonitis"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Active non-infectious pneumonitis""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""history of grade 3 non-infectious pneumonitis"",
        ""temporal"": {
            ""start"": {
                ""number"": 12,
                ""unit"": ""months""
            },
            ""reference_event"": 1
        }
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""history of grade 4 non-infectious pneumonitis"",
        ""temporal"": {
            ""start"": {
                ""number"": 12,
                ""unit"": ""months""
            },
            ""reference_event"": 1
        }
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""requiring steroids""
    }
]
```"
NCT02595866,Exclusion: Grade 3-4 ascites or pleural effusion,"```json
[
    {
        ""entity"": ""Grade 3-4"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""ascites"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""pleural effusion"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""ascites""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""pleural effusion""
    }
]
```"
NCT02595866,"Exclusion: Receipt of live vaccines within 30 days before the first dose of trial treatment and while participating in the trial; examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, seasonal flu, H1N1 flu, rabies, bacillus Calmette-Guerin (BCG), and typhoid vaccine","```json
[
    {
        ""entity"": ""Receipt of live vaccines"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""within 30 days"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""before the first dose of trial treatment"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""while participating in the trial"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""measles"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""mumps"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""rubella"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""chicken pox"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""yellow fever"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""seasonal flu"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""H1N1 flu"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""rabies"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""bacillus Calmette-Guerin (BCG)"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""typhoid vaccine"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Procedure/Device"",
        ""name"": ""Receipt of live vaccines"",
        ""temporal"": {
            ""start"": {
                ""number"": 30,
                ""unit"": ""days""
            },
            ""reference_event"": 2
        }
    },
    {
        ""id"": 2,
        ""type"": ""Procedure/Device"",
        ""name"": ""first dose of trial treatment""
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""measles""
    },
    {
        ""id"": 4,
        ""type"": ""Drug/Substance"",
        ""name"": ""mumps""
    },
    {
        ""id"": 5,
        ""type"": ""Drug/Substance"",
        ""name"": ""rubella""
    },
    {
        ""id"": 6,
        ""type"": ""Drug/Substance"",
        ""name"": ""chicken pox""
    },
    {
        ""id"": 7,
        ""type"": ""Drug/Substance"",
        ""name"": ""yellow fever""
    },
    {
        ""id"": 8,
        ""type"": ""Drug/Substance"",
        ""name"": ""seasonal flu""
    },
    {
        ""id"": 9,
        ""type"": ""Drug/Substance"",
        ""name"": ""H1N1 flu""
    },
    {
        ""id"": 10,
        ""type"": ""Drug/Substance"",
        ""name"": ""rabies""
    },
    {
        ""id"": 11,
        ""type"": ""Drug/Substance"",
        ""name"": ""bacillus Calmette-Guerin (BCG)""
    },
    {
        ""id"": 12,
        ""type"": ""Drug/Substance"",
        ""name"": ""typhoid vaccine""
    }
]
```"
NCT02595866,Exclusion: History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 (pembrolizumab),"```json
[
    {
        ""entity"": ""History of allergic reactions"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""compounds of similar chemical or biologic composition to MK-3475 (pembrolizumab)"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""History of allergic reactions""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""compounds of similar chemical or biologic composition to MK-3475 (pembrolizumab)""
    }
]
```"
NCT04140526,"Inclusion: . Patients must have a histological or cytological diagnosis of NSCLC or any other type of carcinoma or sarcomas, progressive metastatic disease, or progressive locally advanced disease not amenable to local therapy.","```json
[
    {
        ""entity"": ""histological or cytological diagnosis"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""NSCLC"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""carcinoma"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""sarcomas"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""progressive metastatic disease"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""progressive locally advanced disease"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""not amenable to local therapy"",
        ""category"": ""Qualifier/Modifier""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""histological or cytological diagnosis""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""NSCLC""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""carcinoma""
    },
    {
        ""id"": 4,
        ""type"": ""Condition"",
        ""name"": ""sarcomas""
    },
    {
        ""id"": 5,
        ""type"": ""Condition"",
        ""name"": ""progressive metastatic disease""
    },
    {
        ""id"": 6,
        ""type"": ""Condition"",
        ""name"": ""progressive locally advanced disease""
    }
]
```"
NCT04140526,Inclusion: Patient is male or female and \>18 years of age on day of signing informed consent.,"```json
[
    {
        ""entity"": "">18 years"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""age"",
        ""category"": ""Observation""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""age"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 18,
                ""unit"": ""years""
            }
        }
    }
]
```"
NCT04140526,Inclusion: Patient must have a performance status of 0 or 1 on the ECOG Performance Scale,"```json
[
    {
        ""entity"": ""performance status"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""0 or 1"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""ECOG Performance Scale"",
        ""category"": ""Observation""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""performance status"",
        ""value"": {
            ""qualitative"": ""0 or 1""
        }
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""ECOG Performance Scale""
    }
]
```"
NCT04140526,Inclusion: Patient must have adequate organ function as indicated by the following laboratory values:,"```json
[
    {
        ""entity"": ""adequate organ function"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""laboratory values"",
        ""category"": ""Observation""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""adequate organ function""
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""laboratory values""
    }
]
```"
NCT04140526,Inclusion: Patient has voluntarily agreed to participate by giving written informed consent.,"```json
[]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Type 2 diabetes mellitus""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""Metformin""
    },
    {
        ""id"": 3,
        ""type"": ""Measurement"",
        ""name"": ""Serum creatinine""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""Chemotherapy""
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""Smoking""
    },
    {
        ""id"": 6,
        ""type"": ""Observation"",
        ""name"": ""30 to 75 years old"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 30,
                ""upper_bound"": 75,
                ""unit"": ""years""
            }
        }
    }
]
```"
NCT04140526,Inclusion: Female patient of childbearing potential has a negative urine or serum pregnancy test.,"```json
[
    {
        ""entity"": ""Female"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""childbearing potential"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""negative"",
        ""category"": ""Qualifiers/Modifiers""
    },
    {
        ""entity"": ""urine or serum pregnancy test"",
        ""category"": ""Observation""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""Female""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""childbearing potential""
    },
    {
        ""id"": 3,
        ""type"": ""Observation"",
        ""name"": ""urine or serum pregnancy test"",
        ""value"": {
            ""qualitative"": ""negative""
        }
    }
]
```"
NCT04140526,Inclusion: Female and Male patients must agree to use adequate methods of contraception starting with the first dose of study drug through 90 days after the last dose of study therapy.,"```json
[]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Type 2 diabetes mellitus""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""Metformin""
    },
    {
        ""id"": 3,
        ""type"": ""Measurement"",
        ""name"": ""Serum creatinine""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""Chemotherapy""
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""Smoking""
    },
    {
        ""id"": 6,
        ""type"": ""Observation"",
        ""name"": ""30 to 75 years old"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 30,
                ""upper_bound"": 75,
                ""unit"": ""years""
            }
        }
    }
]
```"
NCT04140526,"Exclusion: Patients who have not recovered to CTCAE ≤ 1 from the AE due to cancer therapeutics. The washout period for cancer therapeutic drugs (such as chemotherapy, radioactive, or targeted therapy) is 21 days, and for antibody drug 28 days.","```json
[
    {
        ""entity"": ""CTCAE ≤ 1"",
        ""category"": ""Measurement""
    },
    {
        ""entity"": ""AE"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""cancer therapeutics"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""washout period"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""cancer therapeutic drugs"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""chemotherapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""radioactive"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""targeted therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""21 days"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""antibody drug"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""28 days"",
        ""category"": ""Temporal Constraints""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""AE""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""cancer therapeutics""
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""cancer therapeutic drugs""
    },
    {
        ""id"": 4,
        ""type"": ""Drug/Substance"",
        ""name"": ""chemotherapy""
    },
    {
        ""id"": 5,
        ""type"": ""Drug/Substance"",
        ""name"": ""radioactive""
    },
    {
        ""id"": 6,
        ""type"": ""Drug/Substance"",
        ""name"": ""targeted therapy""
    },
    {
        ""id"": 7,
        ""type"": ""Drug/Substance"",
        ""name"": ""antibody drug""
    }
]
```"
NCT04140526,Exclusion: Patients who are currently enrolled in a clinical trial of an investigational agent or device.,"```json
[]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""Type 2 diabetes mellitus""
    },
    {
        ""id"": 2,
        ""type"": ""Drug/Substance"",
        ""name"": ""Metformin""
    },
    {
        ""id"": 3,
        ""type"": ""Measurement"",
        ""name"": ""Serum creatinine""
    },
    {
        ""id"": 4,
        ""type"": ""Procedure/Device"",
        ""name"": ""Chemotherapy""
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""Smoking""
    },
    {
        ""id"": 6,
        ""type"": ""Observation"",
        ""name"": ""30 to 75 years old"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 30,
                ""upper_bound"": 75,
                ""unit"": ""years""
            }
        }
    }
]
```"
NCT04140526,Exclusion: Patients who are on chronic systemic steroid therapy at doses \>10 mg/day,"```json
[
    {
        ""entity"": ""chronic systemic steroid therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": "">10 mg/day"",
        ""category"": ""Measurement""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Drug/Substance"",
        ""name"": ""chronic systemic steroid therapy"",
        ""value"": {
            ""range"": {
                ""lower_bound"": 10,
                ""unit"": ""mg/day""
            }
        }
    }
]
```"
NCT04140526,Exclusion: Patients who have active symptomatic brain metastasis or leptomeningeal metastasis.,"```json
[
    {
        ""entity"": ""active symptomatic brain metastasis"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""leptomeningeal metastasis"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""active symptomatic brain metastasis""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""leptomeningeal metastasis""
    }
]
```"
NCT04140526,Exclusion: Patients who have an active infection requiring systemic IV therapy within 14 days of prior to administration of ONC-392 or combined ONC-392 and Pembrolizumab.,"```json
[
    {
        ""entity"": ""active infection"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""requiring systemic IV therapy"",
        ""category"": ""Procedure/Device""
    },
    {
        ""entity"": ""within 14 days"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""prior to administration of ONC-392 or combined ONC-392 and Pembrolizumab"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""ONC-392"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""combined ONC-392 and Pembrolizumab"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""Pembrolizumab"",
        ""category"": ""Drug/Substance""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""active infection""
    },
    {
        ""id"": 2,
        ""type"": ""Procedure/Device"",
        ""name"": ""requiring systemic IV therapy"",
        ""temporal"": {
            ""start"": {
                ""number"": 14,
                ""unit"": ""days""
            },
            ""reference_event"": 3
        }
    },
    {
        ""id"": 3,
        ""type"": ""Drug/Substance"",
        ""name"": ""ONC-392""
    },
    {
        ""id"": 4,
        ""type"": ""Drug/Substance"",
        ""name"": ""combined ONC-392 and Pembrolizumab""
    },
    {
        ""id"": 5,
        ""type"": ""Drug/Substance"",
        ""name"": ""Pembrolizumab""
    }
]
```"
NCT04140526,"Exclusion: Patients who have a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator.","```json
[
    {
        ""entity"": ""history"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""current evidence"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""condition"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""therapy"",
        ""category"": ""Drug/Substance""
    },
    {
        ""entity"": ""laboratory abnormality"",
        ""category"": ""Observation""
    },
    {
        ""entity"": ""full duration of the study"",
        ""category"": ""Temporal Constraints""
    },
    {
        ""entity"": ""opinion of the treating Investigator"",
        ""category"": ""Observation""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Observation"",
        ""name"": ""history""
    },
    {
        ""id"": 2,
        ""type"": ""Observation"",
        ""name"": ""current evidence""
    },
    {
        ""id"": 3,
        ""type"": ""Condition"",
        ""name"": ""condition""
    },
    {
        ""id"": 4,
        ""type"": ""Drug/Substance"",
        ""name"": ""therapy""
    },
    {
        ""id"": 5,
        ""type"": ""Observation"",
        ""name"": ""laboratory abnormality""
    },
    {
        ""id"": 6,
        ""type"": ""Observation"",
        ""name"": ""opinion of the treating Investigator""
    }
]
```"
NCT04140526,Exclusion: Patients with known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.,"```json
[
    {
        ""entity"": ""psychiatric disorders"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""substance abuse disorders"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""psychiatric disorders""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""substance abuse disorders""
    }
]
```"
NCT04140526,Exclusion: Patients who are pregnant or breastfeeding.,"```json
[
    {
        ""entity"": ""pregnant"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""breastfeeding"",
        ""category"": ""Condition""
    }
]
```","```python
def extract_events(inputs: Dict[str, Any]) -> str:
    """"""
    This function is used to identify and extract structured events and attributes related to the specified entities from the input text.
    The entities, along with their types and names, have been identified in a previous step and are provided for reference.

    The function takes a dictionary of `inputs` as an argument, which contains the following keys:
    - 'input_text': the input eligibility criteria in text format
    - 'entities': a list of entities, each containing the type and name of an entity identified in the input text
        e.g., [""Condition: Type 2 diabetes mellitus"", ""Drug/Substance: Metformin"", ""Measurement: Serum creatinine"", ""Procedure/Device: Chemotherapy"", ""Observation: Smoking"", ""Observation: 30 to 75 years old"", ...]

    The function should return a list of dictionaries, each containing the extracted events and attributes for the specified entities.
    - Event entity types include: `Condition`, `Observation`, `Procedure/Device`, `Drug/Substance`.
    - Attribute entities include: `Measurement`, `Temporal Constraints`, `Qualifiers/Modifiers`.

    The formats of the target extracted events are as follows:


    Observation:
    {
        ""id"": int, \\ the unique identifier of the event, starting from 1 to N
        ""type"":""Observation"",
        ""name"": str, \\ the name of the observation
        ""occurrence"": {
            ""operator"": str, \\ the operator of the occurrence, in [""at least"", ""at most"", ""exactly""]
            ""number"": int, \\ the number of occurrence
        },
        ""temporal"": {
            ""start"": {
                ""number"": int, \\ the number of days/months/years/etc before the reference event
                ""unit"": str, \\ the unit of the temporal, in [""days"", ""weeks"", ""months"", ""years""]
            },
            ""end"":{
                ""number"": int, \\ the number of days/months/years/etc after the reference event
                ""unit"": str, \\ the unit of the temporal, in [""days"", ""weeks"", ""months"", ""years""]
            },
            ""reference_event"": int, \\ the reference event id for the start and end window
        },
        ""value"":{
            ""range"": {
                ""lower_bound"": float, \\ the lower bound of the measurement value
                ""upper_bound"": float, \\ the upper bound of the measurement value
                ""unit"": str, \\ the unit of the measurement value
            },
            ""qualitative"": str, \\  the qualitative value of the measurement, e.g., ""positive"", ""negative"", ""normal"", ""abnormal"", etc.
        },
    }

    Condition:
    {
        ""id"": int, \\ the unique identifier of the event, starting from 1 to N
        ""type"":""Condition"", \\ the type of the entity
        ""name"": str, \\ the name of the condition
        ""occurrence"": {
            ""operator"": str, \\ the operator of the occurrence, in [""at least"", ""at most"", ""exactly""]
            ""number"": int, \\ the number of occurrences 
            }},
        ""temporal"": {
            ""start"": {
                ""number"": int, \\ the number of days/months/years/etc before the reference event
                ""unit"": str, \\ the unit of the temporal, in [""days"", ""weeks"", ""months"", ""years""]
            },
            ""end"":{
                ""number"": int, \\ the number of days/months/years/etc after the reference event
                ""unit"": str, \\ the unit of the temporal, in [""days"", ""weeks"", ""months"", ""years""]
            },
            ""reference_event"": int, \\ the reference event id for the start and end window
        }}
    }

    Drug/Substance:
    {
        ""id"": int, \\ the unique identifier of the event, starting from 1 to N
        ""type"":""Drug/Substance"",
        ""name"": str, \\ the name of the drug
        ""occurrence"": {
            ""operator"": str, \\ the operator of the occurrence, in [""at least"", ""at most"", ""exactly""]
            ""number"": int, \\ the number of occurrence
        },
        ""temporal"": {
            ""start"": {
                ""number"": int, \\ the number of days/months/years/etc before the reference event
                ""unit"": str, \\ the unit of the temporal, in [""days"", ""weeks"", ""months"", ""years""]
            },
            ""end"":{
                ""number"": int, \\ the number of days/months/years/etc after the reference event
                ""unit"": str, \\ the unit of the temporal, in [""days"", ""weeks"", ""months"", ""years""]
            },
            ""reference_event"": int, \\ the reference event id for the start and end window
        }}
    }


    Procedure/Device:
    {
        ""id"": int, \\ the unique identifier of the event, starting from 1 to N
        ""type"":""Procedure/Device"",
        ""name"": str, \\ the name of the procedure
        ""occurrence"": {
            ""operator"": str, \\ the operator of the occurrence, in [""at least"", ""at most"", ""exactly""]
            ""number"": int, \\ the number of occurrence
        },
        ""temporal"": {
            ""start"": {
                ""number"": int, \\ the number of days/months/years/etc before the reference event
                ""unit"": str, \\ the unit of the temporal, in [""days"", ""weeks"", ""months"", ""years""]
            },
            ""end"":{
                ""number"": int, \\ the number of days/months/years/etc after the reference event
                ""unit"": str, \\ the unit of the temporal, in [""days"", ""weeks"", ""months"", ""years""]
            },
            ""reference_event"": int, \\ the reference event id for the start and end window
        }}
    }}

    IMPORTANT: 
    - for all the events, the fields 'id', 'type', 'name' are mandatory, the other fields are optional and should be included only if they are present in the input text.
    - for all the events, the field 'type' must be one of the following: 'Condition', 'Observation', 'Procedure/Device', 'Drug/Substance'.

    The function should return a syntactically correct JSON format string that contains a list of the extracted events, each event should be one of the above formats.
    The output is wrapped within  ```json and ``` tags, for example:
    ```json
    [
        {
            ""id"": 1, \\ the unique identifier of the event, starting from 1 to N
            ""type"":""Observation"", \\ the type of the entity
            ""name"": ""age"", \\ the name of the observation
            ""value"":{
                ""range"": {
                    ""lower_bound"": float, \\ the lower bound of the age value
                    ""upper_bound"": float, \\ the upper bound of the age value
                    ""unit"": str, \\ the unit of the age value
                }},
        },
        ... \\ other events
    ]
    ```

    Returns:
    - str: a JSON format string that contains a list of the extracted events, wrapped by ```json and ``` tags
    """"""
```
Please pretend you are the function and ensure you generate the json output as expected, and the output is wrapped within ```json and ``` tags.

# Provided inputs
input_text = """"""Participants must not be pregnant or breastfeeding.""""""
entities = """"""[
    {
        ""entity"": ""pregnant"",
        ""category"": ""Condition""
    },
    {
        ""entity"": ""breastfeeding"",
        ""category"": ""Condition""
    }
]""""""

inputs = {
    ""input_text"": input_text,
    ""entities"": entities
}
```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""pregnant""
    },
    {
        ""id"": 2,
        ""type"": ""Condition"",
        ""name"": ""breastfeeding""
    }
]
```"
NCT04140526,"Exclusion: For the Part B and Part C Arm D to G, the patients that are deemed to be not suitable for Pembrolizumab.","```json
[
    {
        ""entity"": ""not suitable for Pembrolizumab"",
        ""category"": ""Condition""
    }
]
```","```json
[
    {
        ""id"": 1,
        ""type"": ""Condition"",
        ""name"": ""not suitable for Pembrolizumab""
    }
]
```"
